

PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : A01N 37/00	A1	(11) International Publication Number: WO 98/47360 (43) International Publication Date: 29 October 1998 (29.10.98)
(21) International Application Number: PCT/US98/08082 (22) International Filing Date: 15 April 1998 (15.04.98) (30) Priority Data: 60/044,556 24 April 1997 (24.04.97) US (71) Applicant: BRISTOL-MYERS SQUIBB COMPANY [US/US]; 5 Research Parkway, Wallingford, CT 06492 (US). (72) Inventors: MASTALERZ, Harold; 70 Robin Lane, Guilford, CT 06437 (US). KADOW, John, F.; 9 Quarry Run, Wallingford, CT 06492 (US). (74) Agent: DUBOFF, Samuel, J.; Bristol-Myers Squibb Company, 5 Research Parkway, Wallingford, CT 06492 (US).	(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG). Published <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>	
(54) Title: 7-SULFUR SUBSTITUTED PACLITAXELS (57) Abstract The present invention concerns novel taxane derivatives, their use as antitumor agents, and pharmaceutical formulations.		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

7-SULFUR SUBSTITUTED PACLITAXELS

Field of the Invention

5 The present invention concerns antitumor compounds. More particularly, the invention provides novel paclitaxel derivatives, pharmaceutical formulations thereof, and their use as antitumor agents.


Background Art

10

Taxol® (paclitaxel) is a natural product extracted from the bark of Pacific yew trees, *Taxus brevifolia*. It has been shown to have excellent antitumor activity in in vivo animal models, and recent studies have elucidated its unique mode of action, which involves abnormal
15 polymerization of tubulin and disruption of mitosis. It has recently been approved for the treatment of refractory advanced ovarian cancer and breast cancer; and studies involving other cancers have shown promising results. The results of paclitaxel clinical studies are reviewed by numerous authors, such as by Rowinsky and Donehower in "The Clinical
20 Pharmacology and Use of Antimicrotubule Agents in Cancer Chemotherapeutics," Pharmac. Ther., 52:35-84, 1991; by Spencer and Faulds in "Paclitaxel, A Review of its Pharmacodynamic and Pharmacokinetic Properties and Therapeutic Potential in the Treatment of Cancer," Drugs, 48 (5) 794-847, 1994; by K.C. Nicolaou et al. in "Chemistry
25 and Biology of Taxol," Angew. Chem., Int. Ed. Engl., 33: 15-44, 1994; by F.A. Holmes, A.P. Kudelka, J.J. Kavanaugh, M. H. Huber, J. A. Ajani, V. Valero in the book "Taxane Anticancer Agents Basic Science and Current Status" edited by Gunda I. Georg, Thomas T. Chen, Iwao Ojima, and Dolotrai M. Vyas, 1995, American Chemical Society, Washington, DC, 31-
30 57; by Susan G. Arbuck and Barbara Blaylock in the book "TAXOL® Science and Applications" edited by Mathew Suffness, 1995, CRC Press Inc., Boca Raton, Florida, 379-416; and also in the references cited therein.

A semi-synthetic analog of paclitaxel named Taxotere® (docetaxel)
35 has also been found to have good antitumor activity. The structures of paclitaxel and Taxotere® are shown below along with the conventional

numbering system for molecules belonging to the class; such numbering system is also employed in this application.



5


Taxol®: R = Ph; R' = acetyl

Taxotere®: R = t-butoxy; R' = hydrogen

10

SUMMARY OF THE INVENTION

This invention relates to novel antitumor compounds represented by formula I, or pharmaceutically acceptable salts thereof



15

I

wherein R is hydrogen, C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, or -Z¹-R³;

Z¹ is a direct bond, C₁₋₆ alkyl, or -O-C₁₋₆ alkyl;

20

R³ is aryl, substituted aryl, C₃₋₆ cycloalkyl, C₃₋₆ cycloalkenyl, cyclic 3-7 membered ring containing either one or two heteroatoms, or heteroaryl;

R^A is -NHC(O)R, -NHC(O)OR, -NHC(O)NHR, -NHC(O)N(R)₂, -NHS(O)_kR, -NHP(=O)(OR)₂ or -NHP=S(OR)₂, where k is 1 or 2;

25

R^B is hydroxy, fluoro, $-OC(O)R^x$, $-OC(O)OR^x$, $OP(O)(OH)_2$,
 $OCH_2OP(O)(OH)_2$, $-OCH_2OCH_2OP(=O)(OH)_2$, $OP(O)(OH)_2$ base,
 $OCH_2OP(O)(OH)_2$ base, $-OCH_2OCH_2OP(=O)(OH)_2$ base,
 $-(OCH_2)_mOC=OCH_2NHR^x$, $-(OCH_2)_mOC(=O)CH(R'')NR'_6R'_7$, where m is
 5 0-3, $-OCOCH_2CH_2NH_3^+HCOO^-$, $-OCOCH_2CH_2COOH$, $-OCO(CH_2)_3COOH$,
 $-OC(O)(CH_2)_nNR^FR^G$, where n is 0-3, $-OC(O)CH_2CH_2C(O)OCH_2CH_2OH$ or
 $-OC(O)-Z-C(O)-R'$;

Z is ethylene ($-CH_2CH_2-$), propylene ($-CH_2CH_2CH_2-$), $-CH=CH-$,
 10 1,2-cyclohexane or 1,2-phenylene;

R' is $-OH$, $-OH$ base, $-NR'_2R'_3$, $-OR'_3$, $-SR'_3$, or $-OCH_2C(O)NR'_4R'_5$;

R'_2 is $-H$ or $-CH_3$;

15 R'_3 is $-(CH_2)_jNR'_6R'_7$ or $(CH_2)_nN^+R'_6R'_7R'_8X^-$, where j is 1-3;

R'_4 is $-H$ or $-C_1-C_4$ alkyl;

20 R'_5 is $-H$, $-C_1-C_4$ alkyl, benzyl, hydroxyethyl, $-CH_2CO_2H$ or
 dimethylaminoethyl;

R'_6 and R'_7 are independently $-H$, $-CH_3$, $-CH_2CH_3$, benzyl or R'_6 and R'_7
 together with the nitrogen of $NR'_6R'_7$ form a pyrrolidino, piperidino,
 25 morpholino, or N-methylpiperizino group;

R'_8 is $-CH_3$, $-CH_2CH_3$ or benzyl;

X^- is halide;

30 base is NH_3 , $(HOC_2H_4)_3N$, $N(CH_3)_3$, $CH_3N(C_2H_4)_2NH$, $NH_2(CH_2)_6NH_2$,
 N-methylglucamine, NaOH or KOH;

R^F and R^G are independently $-H$ or $-C_1-C_3$ alkyl, or R^F and R^G taken
 35 together with the nitrogen of NR^FR^G form a pyrrolidino, piperidino,
 morpholino or N-methylpiperizino groups;

R'' is -H, -CH₃, -CH₂CH(CH₃)₂, -CH(CH₃)CH₂CH₃, -CH(CH₃)₂,
 -CH₂phenyl, -(CH₂)₃NH₂, -(CH₂)₄NH₂, -CH₂CH₂COOH,
 -(CH₂)₃NHC(=NH)NH₂, the residue of the amino acid proline,
 -OC(O)CH=CH₂, -C(O)CH₂CH₂C(O)NHCH₂CH₂SO₃-Y⁺ or
 5 -OC(O)CH₂CH₂C(O)NHCH₂CH₂CH₂SO₃-Y⁺;

Y⁺ is Na⁺ or N⁺(Bu)₄;

R² is aryl or substituted aryl;

10

R⁴ is -C₁₋₆ alkyl, -O-C₁₋₆ alkyl, or -C₃₋₆ cycloalkyl;

R⁶ and R^{6'} are independently hydrogen, hydroxy, C₁₋₆ alkyl, -SH, -S-R^W,
 halo, or together R⁶ and R^{6'} form a ketone;

15

R⁷ and R^{7'} are independently hydrogen, mercapto, -S-R^W, -S(R^W)₂⁺ K⁻,
 -S(O)-R^W, -S(O)₂R^W, -S(O)₂OH and the corresponding salts, -S(O)₂NHR^x,
 -S(O)₂N(R^x)₂, -S-S-R^W, -S-S-R³, -S(CH₂)_aR³, where a is 0-4, -S-CN,
 -S(O)-CN, -S(O)₂-CN, -SC(O)R^x, -SC(O)OR^x, -SC(S)R^x, -SC(S)SR^x,
 20 -SC(O)NHR^x, -SC(O)NR⁶R⁷, -SCH₂OR, -SC(R^x)₂OR, -SCHR^xOR,
 -SCH₂OCH₂OCH₃, -SCH₂SR, -SC(R^x)₂SR, -SCHR^xSR, -SCOCH₂CH₂NH₃⁺
 HCOO⁻, -SCOCH₂CH₂COOH, -SCO(CH₂)₃COOH, -OC(O)(CH₂)_nNR^FR^G,
 where n is 0-3, -SC(O)-Z-C(O)-R', -SC(O)CH₂CH₂C(O)OCH₂CH₂OH,
 -S(O)_bCH₂CN, where b is 0-2, -SCH₂C(O)C₁₋₆ alkyl, -SCH=C(X)(Y),
 25 -S(CH₂)_rR², where r is 1-4, or -S(CH₂)S(O)_tC₁₋₆ alkyl, where t is 0-2, with
 the proviso that both of R⁷ and R^{7'} cannot simultaneously be hydrogen;

X and Y are independently hydrogen, COOR^a, C(O)R^a, R^a, CN, aryl or
 30 heteroaryl, where R^a is C₁₋₆ alkyl;

K is Br⁻, Cl⁻, I⁻, CH₃SO₃⁻, BF₄⁻, CF₃COO⁻, CH₃COO⁻ or CF₃SO₂⁻;

R⁹ and R^{9'} are independently hydrogen or hydroxy or together R⁹ and R^{9'}
 35 form a ketone; provided R^{9'} and R^{7'} taken together can form part of a ring
 joined by -CH₂S(O)_q- in which the carbon is attached at R^{9'} and the sulfur
 at R^{7'} and where q is 0-2, R⁹ is -OH, and R⁷ is hydrogen; further provided
 R^{9'} and R^{7'} taken together can form part of a ring joined by =CHS(O)_q- in

which the carbon is attached at R⁹ and R^{9'} to form a double bond and the sulfur at R⁷ and where q is 0-2, and R⁷ is hydrogen;

- R¹⁰ is hydrogen, hydroxy, -OC(O)R^x, -OC(O)OR^x, -O-C₁₋₆ alkyl,
 5 -OCH₂OCH₃, -OCH₂OCH₂OCH₃, -OCH₂OCH₂OCH₂CH₃,
 -OCH₂OCH₂CH₂OCH₃, -OCH₂OCH₂CH₂OH, -OCH₂SR,
 -OCH₂OCH₂SCH₃, -OC(O)NR'₆R'₇, C₁₋₆ alkyl,
 -(CH₂)₃C(O)R^x, -(CH₂)₃C(O)OR^x, -(CH₂)₃CN, -OP(O)(OH)₂,
 -OCH₂OP(O)(OH)₂, -OCH₂OCH₂OP(O)(OH)₂, -(OCH₂)_nOC=OCH₂NHR^x,
 10 -(OCH₂)_nOC(=O)CH(R'')NR'₆R'₇, where n is 0-3, -OCOCH₂CH₂NH₃⁺
 HCOO⁻, -OCOCH₂CH₂COOH, -OCO(CH₂)₃COOH, -OC(O)-Z-C(O)-R',
 -OC(O)(CH₂)_nNR^FR^G where n is 0-3, or -OC(O)CH₂CH₂C(O)OCH₂CH₂OH;


- R¹⁹ is methyl or hydroxymethyl;

- 15 R^x is C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₃₋₆ cyclo alkyl, any of which groups can be optionally substituted with one to six of the same or different halogen atoms or with one or more hydroxy groups; and
- 20 R^W is C₁₋₆ alkyl any of which groups can be optionally substituted with one to six of the same or different halogen atoms or with one or more hydroxy groups or with one or more carboxy groups or with one or more carboxy C₁₋₆ alkyl esters or with one or more mercapto groups.

- 25 Another aspect of the present invention provides a method for inhibiting tumor in a mammalian host which comprises administering to said mammalian host an antitumor effective amount of a compound of formula I.

- 30 Yet, another aspect of the present invention provides a pharmaceutical formulation which comprises an antitumor effective amount of a compound of formula I in combination with one or more pharmaceutically acceptable carriers, excipients, diluents or adjuvants.

- 35 Another aspect of the invention provides for novel baccatin intermediate compounds of formula II



II

DETAILED DESCRIPTION

5

In the application, unless otherwise specified explicitly or in context, the following definitions apply. The numbers in the subscript after the symbol "C" define the number of carbon atoms a particular group can contain. For example "C₁₋₆ alkyl" means a straight or branched saturated carbon chain having from one to six carbon atoms; examples include methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, t-butyl, n-pentyl, sec-pentyl, isopentyl, and n-hexyl. Depending on the context, "C₁₋₆ alkyl" can also refer to C₁₋₆ alkylene which bridges two groups; examples include propane-1,3-diyl, butane-1,4-diyl, 2-methyl-butane-1,4-diyl, etc. "C₂₋₆ alkenyl" means a straight or branched carbon chain having at least one carbon-carbon double bond, and having from two to six carbon atoms; examples include ethenyl, propenyl, isopropenyl, butenyl, isobutenyl, pentenyl, and hexenyl. Depending on the context, "C₂₋₆ alkenyl" can also refer to C₂₋₆ alkenediyl which bridges two groups; examples include ethylene-1,2-diyl (vinylene), 2-methyl-2-butene-1,4-diyl, 2-hexene-1,6-diyl, etc. "C₂₋₆ alkynyl" means a straight or branched carbon chain having at least one carbon-carbon triple bond, and from two to six carbon atoms; examples include ethynyl, propynyl, butynyl, and hexynyl.

25

"Aryl" means aromatic hydrocarbon having from six to ten carbon atoms; examples include phenyl and naphthyl. "Substituted aryl" means aryl independently substituted with one to five (but preferably one to three) groups selected from C₁₋₆ alkanoyloxy, hydroxy, halogen, C₁₋₆ alkyl, trifluoromethyl, C₁₋₆ alkoxy, aryl, C₂₋₆ alkenyl, C₁₋₆ alkanoyl, nitro,

amino, cyano, azido, C₁₋₆ alkylamino, di-C₁₋₆ alkylamino, and amido.

"Halogen" means fluorine, chlorine, bromine, and iodine.

"Heteroaryl" means a five- or six-membered aromatic ring
5 containing at least one and up to four non-carbon atoms selected from
oxygen, sulfur and nitrogen. Examples of heteroaryl include thienyl,
furyl, pyrrolyl, imidazolyl, pyrazolyl, thiazolyl, isothiazolyl, oxazolyl,
isoxazolyl, triazolyl, thiadiazolyl, oxadiazolyl, tetrazolyl, thiatriazolyl,
oxatriazolyl, pyridyl, pyrimidyl, pyrazinyl, pyridazinyl, triazinyl,
10 tetrazinyl, and like rings.

"Hydroxy protecting groups" include, but is not limited to, ethers
such as methyl, t-butyl, benzyl, p-methoxybenzyl, p-nitrobenzyl, allyl,
trityl, methoxymethyl, methoxyethoxymethyl, ethoxyethyl,
15 tetrahydropyranyl, tetrahydrothiopyranyl, dialkylsilylethers, such as
dimethylsilyl ether, and trialkylsilyl ethers such as trimethylsilyl ether,
triethylsilyl ether, and t-butyl dimethylsilyl ether; esters such as benzoyl,
acetyl, phenylacetyl, formyl, mono-, di-, and trihaloacetyl such as
chloroacetyl, dichloroacetyl, trichloroacetyl, trifluoroacetyl; and carbonates
20 such as methyl, ethyl, 2,2,2-trichloroethyl, allyl, benzyl, and p-nitrophenyl.
Additional examples of hydroxy protecting groups may be found in
standard reference works such as Greene and Wuts, Protective Groups in
Organic Synthesis, 2d Ed., 1991, John Wiley & Sons, and McOmie; and
Protective Groups in Organic Chemistry, 1975, Plenum Press.

25 "Ph" means phenyl; "ipr" means isopropyl; "DAST" means
diethylamino sulfur trifluoride.

The substituents of the substituted alkyl, alkenyl, alkynyl, aryl, and
30 heteroaryl groups and moieties described herein, may be alkyl, alkenyl,
alkynyl, aryl, heteroaryl and/or may contain nitrogen, oxygen, sulfur,
halogens and include, for example, lower alkoxy such as methoxy, ethoxy,
butoxy, halogen such as chloro or fluoro, nitro, amino, and keto.

35 A preferred embodiment are compounds I, or pharmaceutically
acceptable salts thereof, wherein additionally:

R is 2-furanyl (2-furyl), 2-thienyl, 3-furanyl (3-furyl), 3-thienyl, phenyl, substituted phenyl, C₃₋₆ alkyl, C₃₋₆ alkenyl, C₃₋₆ cycloalkyl or C₃₋₆ cycloalkenyl;

- 5 R^A is -NHC(O)Ph, wherein Ph is substituted or unsubstituted, -NHC(O)O(C₁₋₆ alkyl), -NHC(O)OCH₂Ph, NHC(O)-heterocycle, -NHC(O)NHR or -NHC(O)N(R)₂;

- Another preferred embodiment are compounds I, or
10 pharmaceutically acceptable salts thereof, wherein additionally:

R is phenyl, mono or di-substituted phenyl, C₃₋₆ cycloalkyl, C₃₋₆ alkyl, C₃₋₆ alkenyl or C₃₋₆ cycloalkenyl;

- 15 R² is phenyl or substituted phenyl;

- R^B is hydroxy, -OC(O)R^x, -OC(O)OR^x, OP(O)(OH)₂, OCH₂OP(O)(OH)₂, -OCH₂OCH₂OP(=O)(OH)₂, OP(O)(OH)₂ base, OCH₂OP(O)(OH)₂ base, -OCH₂OCH₂OP(=O)(OH)₂ base, -(OCH₂)_mOC=OCH₂NHR^x,
20 -(OCH₂)_mOC(=O)CH(R'')NR'₆R'₇ where m is 0-3, -OCOCH₂CH₂NH₃⁺, HCOO⁻, -OCOCH₂CH₂COOH, -OCO(CH₂)₃COOH, -OC(O)(CH₂)_nNR^FR^G, where n is 0-3, -OC(O)CH₂CH₂C(O)OCH₂CH₂OH or -OC(O)-Z-C(O)-R';

- R¹⁰ is hydrogen, hydroxy, -OC(O)R^x, -OC(O)OR^x, -O-C₁₋₆ alkyl or
25 -OCH₂OCH₃;

- The new products that have the general formula I display a significant inhibitory effect with regard to abnormal cell proliferation, and have therapeutic properties that make it possible to treat patients who
30 have pathological conditions associated with an abnormal cell proliferation. The pathological conditions include the abnormal cellular proliferation of malignant or non-malignant cells in various tissues and/or organs, including, non-limitatively, muscle, bone and/or conjunctive tissues; the skin, brain, lungs and sexual organs; the
35 lymphatic and/or renal system; mammary cells and/or blood cells; the liver, digestive system, and pancreas; and the thyroid and/or adrenal glands. These pathological conditions can also include psoriasis; solid tumors; ovarian, breast, brain, prostate, colon, stomach, kidney, and/or

testicular cancer, Karposi's sarcoma; cholangiocarcinoma; choriocarcinoma; neuroblastoma; Wilm's tumor, Hodgkin's disease; melanomas; multiple myelomas; chronic lymphocytic leukemias; and acute or chronic granulocytic lymphomas. The novel products in accordance with the invention are particularly useful in the treatment of non-Hodgkin's lymphoma, multiple myeloma, melanoma, and ovarian, urothelial, oesophageal, lung, and breast cancers. The products in accordance with the invention can be utilized to prevent or delay the appearance or reappearance, or to treat these pathological conditions. In addition, the compounds of formula I are useful in treating and/or preventing polycystic kidney diseases (PKD) and rheumatoid arthritis.


The compounds of this invention can be made by techniques from the conventional organic chemistry repertoire. Schemes I - XIII, which depict processes that compounds within the scope of formula I can be made, are only shown for the purpose of illustration and are not to be construed as limiting the processes to make the compounds by any other methods.

The compounds I of this invention are 7- sulfur substituted taxane analogs. All of the contemplated analogs can be prepared from a previously reported 7- triflate intermediate (Scheme I) or suitably substituted analogs. The preparation of this intermediate is shown in Scheme I.

As shown in Scheme I, the starting material is a known taxane analog. The analog with an intact sidechain is suitably protected to leave the most reactive hydroxy group at C-7. Compound 1 in Scheme I is protected at the 2' hydroxy group at the sidechain. Step A describes the protection of the 2' hydroxy group as a 2' tertbutyldimethylsilyl ether. This protecting group is well known in the taxane art and has been described by several authors including Kingston and George. The example of compound 1 actually described utilizes this silyl protecting group at the 2' position. Although this group is preferred, other protecting groups can be utilized. The preparation of intermediate 1 are now well known in the art. The synthesis of the 7-trifluoromethanesulfonate (triflate) intermediate 2 is shown in step B and is by now well known in the art. The preparation of 7-O triflates and its


conversion into cyclopropane and olefin has been divulged by Johnson, R.A., *et al.*, *Taxol chemistry. 7-O-Triflates as precursors to olefins and cyclopropanes. Tetrahedron Letters*, 1994, 35(43): p. 7893-7896 & by the same authors in WO 94/29288. The preferred synthesis utilizes DMAP as the base and triflic anhydride as the activating agent.

Scheme I




The preferred schemes for preparing 7-sulfur derivatives are presented in schemes II-XIII. Other methodologies are contemplated and the syntheses of the desired compounds are not limited to the chemistry which is specifically described.

Scheme II



Scheme III



The triflates **3** are reacted with a nucleophilic thiol reagent to effect displacement and form a C-7 alpha sulfur analog. An example is shown in Scheme 2, step C, in which the the triflate is reacted with lithium methyl mercaptide to produce the 7-alpha methyl sulfide **4**.

Displacements could be effected by other mercaptide salts such as the sodium, potassium, or cesium but the lithium is preferred. The use of free thiols, amine bases such as DBU, and higher temperatures may also be suitable.

Removal of the 2' TBS protecting group in these compounds is effected by tetrabutyl ammonium fluoride in THF solvent. Other fluoride sources could also be utilized. For example triethylamine trihydrofluoride, pyridinium hydrofluoride, potassium fluoride, or

cesium fluoride may find utility. The potassium fluoride may be utilized in combination with a complexing agent such as 18-crown-6 or the like to aid in desilylation. A solvent such as acetonitrile is typically used under these conditions. Other conditions such as mild aqueous hydrochloric acid and a cosolvent such as acetonitrile or THF may be useful for deprotection. The same conditions work equally well for triethylsilyl or trimethylsilyl groups and are applicable for other silicon based protecting groups.


Many of the schemes refer to a hydroxy protecting group, preferably a trialkylsilyl group. It is to be understood that hydroxy protecting group may be a carbonate or ester group $-C(O)OR^x$ or $-C(O)R^x$ or substituted methyl or benzyl ethers. Thus when such a group is employed as a hydroxy protecting group, it may be removed to generate the free hydroxy protecting group. Many suitable protecting groups can be found in the book "Protective Groups in Organic Synthesis; 2nd ed. by Thedora W. Greene and Peter G. M. Wuts Copyright 1991 by John Wiley and Sons Inc."

The 2' protected sulfide intermediate 4 can be oxidized to the intermediate diastereomeric sulfoxides or sulfones. As shown in Scheme 3, step E, oxidation with 2 equivalents of a peracid such as MCPBA produces the sulfone 6, which can subsequently be deprotected as described above to produce the sulfone 7. Utilization of sodium periodate in aqueous methanol solvent or 1 equivalent of MCPBA at low temperature such as -78° in step E would produce the corresponding sulfoxides rather than sulfone. Deprotection as described above would produce the 7-alpha methyl sulfoxide.

As shown in Scheme IV, deprotonation of the sulfone 6 with a strong amine base such as lithium bistrimethylsilylamide and subsequently quenching with a proton source such as aqueous ammonium chloride results in a cyclized product 8, the result of an addition to the C-9 ketone moiety. Deprotection of the 2' hydroxy group as described above for step D provided the fully deprotected compound 9.


35

Scheme IV




Scheme V describes the preparation of C-7 thioesters. Displacement of the triflate 3 with potassium thioacetate as shown in Step H produces the C-7 alpha thioester which is protected at the 2' hydroxy group. Other salts of the thioester or use of the thioacid with Mitsunobu conditions (triphenylphosphine, DEAD) could also be used to produce the same product. Deprotection using the conditions described in Step D above would produce the C-7-alpha thioester analog.

Scheme V




As shown in Scheme VI, Step J, the thioester 10, can be hydrolyzed using
 5 ethanolic ammonia to produce the C-7 alpha thiol substituted taxane 12.
 Epimerization of this thiol moiety as described in Step K produces a
 mixture of the C-7 beta thiol 13 and the starting material 12 in which the
 former predominates. Chromatographic separation provides pure 13.
 Deprotection as described above for Step D produces the beta thiol analog
 10 14 (Scheme VII).

Scheme VI




- The thiol intermediate 13 can be reacted with a wide range of electrophilic reagents to produce the C-7 beta sulfur analogs described in this invention. As described in Scheme VIII, Step M, reaction of the thiol with bromomethyl ether or chloromethyl methyl ether in the presence of a base will produce the desired thioacetal 15. Amine bases in inert solvents such as dichloromethane, 1,2-dichloroethane, or toluene could be utilized. Typical amine bases include triethylamine, diisopropyl ethylamine,

- DMAP, or DBU. Alternatively stronger bases such as lithium (or sodium or potassium) bistrimethylsilylamide or LDA could be utilized typically in solvents such as THF, Dioxane, diethyl ether, or the like. A wide range of temperatures may be employed depending on the reagents and solvent combinations. Step N, the deprotection can be carried out as described above for Step D.


Scheme VII

Scheme VIII




Scheme IX describes the methylation of thiol 13 in Step N in order to produce the methyl sulfide 17. Reaction with methyl iodide and DBU produces the methyl sulfide. Alternatively stronger bases or alternative amine bases could be used. Phase transfer methylation conditions using a methyl iodide, an aqueous base (NaOH, KOH), a phase transfer catalyst (suitable quaternary amine such as Adogen 454) , and an inert solvent such as methylene chloride could be utilized. Other methylating agents such as dimethyl sulfate, methyl bromide, or methyl triflate could be utilized. This methodology could also be used with other alkylating reagents in order to produces sulfides with other than methyl groups. Deprotection as described in Step O (equivalent to Step D) above produces the methyl sulfide 18.

Scheme IX




Another example of thiol alkylation is shown in Scheme X. Reaction of the thiol 13 in an inert solvent such as benzene with ethylene oxide in the presence of DBU produces the 7-beta-hydroxyethyl sulfide 19 which can be deprotected as described above in Step R (equivalent to Step D).

Scheme X




The examples supplied for the current invention describe analogs containing a β -phenyl isoserine C-13 sidechain which is the sidechain found in paclitaxel as well as analogs with alternative, modified sidechains. The entire sequences shown in the Schemes above could be carried out using a starting material 1 which already contains a modified sidechain.

Scheme XI



Scheme XI continued



Alternatively, the paclitaxel sidechain could be cleaved and the resulting substituted baccatin analog reattached to a novel sidechain of choice.


- 5 Scheme XI provides an example of such a sequence using the 7-methylthiomethyl analog 18a as the starting material. Reaction of 18a with tetrabutylammonium borohydride via the method of Magri et. al. in J. Org. Chem. 1986, 51, pp.-3239-3242 provides the 7-sulfur substituted baccatin derivatives such as 21 (Scheme XI). For examples of the use of
- 10 the Magri methodology to prepare other 7-substituted baccatins see U.S. patent 5,254,580 or U.S. patent 5,294,637. These baccatin derivatives can be reacylated by a new sidechain using any of the methodology already well known in the art. For example reaction of 21 with a suitably substituted
- 15 5,229,526; U.S. 5,274,124; U.S. 5,243,045; U.S. 5,227,400; U.S. 5,336,785) provides compound 22. Methods for preparing suitably substituted β -lactams can be found in U.S. patent 5,175,315, European patent application 0 590 267 A2, the other U.S. patents mentioned above, or references therein. Detailed examples of coupling substituted lactams to 7-

substituted baccatin derivatives and the requisite references can be found in U.S. patent 5,254,580, U.S. patent 5,294,637, or EP 0 590 267 A2. Some examples of using β -lactams to prepare other substituted taxane derivatives are in PCT WO/14787. This patent also describes an
5 alternative methods for attaching substituted isoserine sidechains to substituted baccatins which would be applicable for the compounds of this invention. In compound 21, R¹⁰ is acetoxy. In compounds where R¹⁰ is hydroxy, a suitable protecting group must be utilized prior to sidechain cleavage or installed selectively on the C-10 hydroxy group prior to the
10 coupling reaction. Trialkylsilyl, CBz, or Troc protecting groups are suitable for this protecting group step and can be attached using methodology which is well known in the art.

Finally, deprotection of the 2' protecting group as described
15 previously in Step D provides the desired compounds 23 with a modified sidechain. The 2' protecting group is preferably trialkylsilyl but others work as also described in Step D above.

Scheme XII describes one synthesis of 7 vinyl sulfide taxane analogs
20 which are covered by this invention. As shown in Step U, the mercapto taxane intermediate 13 is allowed to add to an appropriate vinyl sulfoxide to form an intermediate beta sulfur substituted sulfoxide. This intermediate 25 could be isolated but it is easier to heat the reaction mixture to effect sulfenic acid elimination and concomitant formation of
25 Compound 26. This compound is then deprotected as previously described in Step D to provide the desired vinyl sulfide Compound 27. While this reaction may be carried out in any inert solvent, toluene or a higher boiling aromatic solvent such as xylene is preferred because the resulting intermediate may be directly heated without isolation to effect
30 sulfoxide elimination and vinyl sulfide formation. DBU is the preferred base but other tertiary amine bases may also be utilized. As described for other schemes, alternate protecting groups of the 2' hydroxy group may be utilized but the tertbutyl dimethylsilyl moiety is the preferred one. Other substituted sulfoxides may be utilized to obtain substituted vinyl
35 compounds. For example utilization of 1-methyl-phenyl vinyl sulfoxide would produce a vinyl sulfide with a methyl group on the 2 position of the olefin.


Scheme XII



- 5 An alternate synthesis of substituted C-7 vinyl sulfide taxane analogs is described in Scheme XIII. The mercapto taxane 13 is allowed to add to an appropriate activated alkyne to provide directly a separable mixture of the protected E or Z substituted vinyl sulfides 32 and 33. It is preferable to separate the isomers prior to removal of the 2' protecting group but it is
- 10 not essential for success of the sequence. The alkyne moiety may be

substituted by any alkyl ester not just the methyl ester. In addition ketones such as methyl ethynyl ketone may be employed in the reaction. The deprotection is carried out as described in the previous schemes (e.g. Step D) to provide the desired Compounds 34 and 35.

5

Scheme XIII

In addition to the methodology described above which utilizes the 7-beta triflate as the starting material for synthesis, the analogs may be prepared from 7-epihydroxy or the 7-epi mesylate starting materials using alternate chemistry and a direct displacement by sulfur nucleophiles to install the sulfur moiety in the beta orientation.

By now there are many publications teaching the introduction of a wide variety of groups onto a taxane core. By using these well established methods or obvious variants thereof, the starting taxanes of formula I or hydroxy protected analogues thereof, can be readily made. For example, for making C7 unsubstituted (deoxy) derivatives see, European Patent Application 590,267A2 published April 6, 1994 and PCT application WO 93/06093 published April 1, 1993; for making C-10 epi hydroxy or acyloxy compounds see PCT application WO 96/03394; for making C-10 deoxy-C-10 alkyl analogs see PCT application WO95/33740; for making 7b,8b-methano, 6a,7a-dihydroxy and 6,7-olefinic groups see, R. A. Johnson, *Tetrahedron Letters*, Vol. 35, No 43, pp 7893-7896 (1994), U.S. Patent No. 5,254,580 issued October 19, 1993, and European Patent Application 600,517A1 published June 8, 1994; for making C7/C6 oxirane see, X. Liang and G.I. Kingston, *Tetrahedron Letters*, Vol. 36, No. 17, pp 2901-2904 (1995); for making C7-epi-fluoro see, G. Roth et al, *Tetrahedron Letters*, Vol 36, pp 1609-1612 (1995); for forming C7 esters and carbonates see, U.S. Patent No. 5,272,171 issued December 21, 1993 and S. H. Chen et al., *Tetrahedron*, 49, No. 14, pp 2805-2828 (1993); for 9a- and 9b-hydroxy taxanes see, L. L. Klein, *Tetrahedron Letters*, Vol 34, No 13, pp 2047-2050 (1993), PCT application WO 94/08984 published April 28, 1994, U.S. Patent No. 5,352,806 issued October 4, 1994, PCT application WO 94/20485 published September 15, 1994, and G.I. Georg et. al. . *Tetrahedron Letters*, Vol 36, No 11, pp 1783-1786 (1995). For making sidechain variations see Robert Holton US patents 5,175,315 and 5,229,526.

DESCRIPTION OF SPECIFIC EMBODIMENTS

The preparation of the starting materials and final products, 1a-35a shown in Table I, which correspond to the the general structures 1-35 in Schemes I-XIII are described in the examples, and in the section just prior to the examples.

TABLE I

<u>Compound</u>	<u>R</u>	<u>R^B</u>	<u>R¹⁰</u>	<u>P_g</u>
1a	Ph-	PhCOHN-	AcO-	-SitBuMe ₂
2a	Ph-	PhCOHN-	AcO-	-SitBuMe ₂
3a	Ph-	PhCOHN-	AcO-	-SitBuMe ₂
4a	Ph-	PhCOHN-	AcO-	-SitBuMe ₂
5a	Ph-	PhCOHN-	AcO-	none
6a	Ph-	PhCOHN-	AcO-	-SitBuMe ₂
7a	Ph-	PhCOHN-	AcO-	none
8a	Ph-	PhCOHN-	AcO-	-SitBuMe ₂
9a	Ph-	PhCOHN-	AcO-	none
10a	Ph-	PhCOHN-	AcO-	-SitBuMe ₂
12a	Ph-	PhCOHN-	AcO-	-SitBuMe ₂
13a	Ph-	PhCOHN-	AcO-	-SitBuMe ₂
14a	Ph-	PhCOHN-	AcO-	none
15a	Ph-	PhCOHN-	AcO-	-SitBuMe ₂
16a	Ph-	PhCOHN-	AcO-	none
17a	Ph-	PhCOHN-	AcO-	-SitBuMe ₂
18a	Ph-	PhCOHN-	AcO-	none
19a	Ph-	PhCOHN-	AcO-	-SitBuMe ₂
20a	Ph-	PhCOHN-	AcO-	none
22a	Ph-	(CH ₃) ₃ COCOHN-	AcO-	none
24a	Ph-	PhCOHN-	AcO-	none
25a	Ph-	PhCOHN-	AcO-	none
27a	Ph-	PhCOHN-	AcO-	none
28a	Ph-	PhCOHN-	AcO-	none
29a,b	Ph-	PhCOHN-	AcO-	none

TABLE I (continued)

Compound	R	R^B	R¹⁰	P_g
30a	Ph-	PhCOHN-	AcO-	none
31a,b	Ph-	PhCOHN-	AcO-	none
34a	Ph-	PhCOHN-	AcO-	none
35a	Ph-	PhCOHN-	AcO-	none

5 The specific examples that follow illustrate the syntheses of the compounds of the instant invention, and is not to be construed as limiting the invention in sphere or scope. The method may be adapted to variations in order to produce the compound embraced by this invention but not specifically disclosed. Further, variations of the methods to
10 produce the same compound in somewhat different manner will also be evident to one skilled in the art.

 In the following experimental procedures, all temperatures are understood to be in Centigrade (C) when not specified. The nuclear
15 magnetic resonance (NMR) spectral characteristics refer to chemical shifts (δ) expressed in parts per million (ppm) versus tetramethylsilane (TMS) as reference standard. The relative area reported for the various shifts in the proton NMR spectral data corresponds to the number of hydrogen atoms of a particular functional type in the molecule. The nature of the shifts as
20 to multiplicity is reported as broad singlet (bs or br s), broad doublet (bd or br d), broad triplet (bt or br t), broad quartet (bq or br q), singlet (s), multiplet (m), doublet (d), quartet (q), triplet (t), doublet of doublet (dd), doublet of triplet (dt), and doublet of quartet (dq). The solvents employed for taking NMR spectra are acetone-d₆ (deuterated acetone). DMSO-d₆
25 (perdeuterodimethylsulfoxide), D₂O (deuterated water), CDCl₃ (deuteriochloroform) and other conventional deuterated solvents. The infrared (IR) spectral description include only absorption wave numbers (cm⁻¹) having functional group identification value.

30 Celite is a registered trademark of the Johns-Manville Products Corporation for diatomaceous earth.

Silica gel used in the following experimentals is silica gel 60 with a particle size 230-400 mesh obtained from EM Separations Technology.

The abbreviations used herein are conventional abbreviations
5 widely employed in the art. Some of which are: DAB (deacetylbaaccatin III); MS (mass spectrometry); HRMS (high resolution mass spectrometry); Ac (acetyl); Ph (phenyl); v/v (volume/volume); FAB (fast atom bombardment); NOBA (m-nitrobenzyl alcohol); min (minute(s)); h or hr(s) (hour(s)); DCC (1,3-dicyclohexylcarbodiimide); BOC (t-
10 butoxycarbonyl); CBZ or Cbz (benzyloxycarbonyl); Bn (benzyl); Bz (benzoyl); Troc (2,2,2-trichloroethyloxycarbonyl), DMS (dimethylsilyl), TBAF (tetrabutylammonium fluoride), DMAP (4-dimethylaminopyridine); TES (triethylsilyl); DMSO (dimethylsulfoxide); THF (tetrahydrofuran); HMDS (hexamethyldisilazane); MeOTf
15 (methyltriflate); NMO (morpholine-N-oxide); (DHQ)₂PHAL (hydroquinine 1,4-phthalazinediyl diether). Tf = triflate =trifluoromethanesulfonate; LRMS (low resolution mass spectrometry); ESI (electrospray ionization); TEMPO (2,2,6,6-tetramethyl-1-piperidinyloxy, free radical); DBU (diazobicycloundecene); MOMCl (chloromethyl methyl
20 ether); TPAP (tetrapropyl ammonium peruthenate); MCPBA (meta chloroperoxy benzoic acid); LDA (lithium diisopropyl amide); DMF (dimethylformamide); TBS (tert-butyl-dimethylsilyl); 18-crown-6 (1, 4, 7, 10, 13, 16-hexaoxacyclo-octadecane); DEAD (diethylazodicarboxylate).

25


Preparation of Starting Materials (Scheme I)

2'-O-(t-butyldimethylsilyl)-paclitaxel [2a]

A solution of paclitaxel (1a)(17.54 gm, 20.54 mmol), imidazole (3.87 gm, 2.8 equiv) and t-butyldimethylsilyl chloride (4.96 gm, 1.6 equiv) in dry N,N-dimethylformamide (42 mL) under a dry nitrogen atmosphere was heated
30 at 60°C for 1.5 hour. After cooling to room temperature, the reaction mixture was partitioned between a mixture of EtOAc : hexane = 3:2 and water. The organic phase was separated and washed with water (3 times) and brine and then dried (Na₂SO₄). Removal of the solvents followed by
35 silica gel column chromatography (elution with 500 mL portions of hexane containing 100, 150, 200, 250, 300 mL of EtOAc) afforded 19.7 gm (99% yield) 2'-O-(t-butyldimethylsilyl)-paclitaxel.

2'-O-(t-Butyldimethylsilyl)-7 β -O-trifluoromethanesulfonylpaclitaxel [3a]

A solution of 2'-O-(t-butyldimethylsilyl)paclitaxel (2a) (19.7 gm, 20.3 mmole) and 4-dimethylaminopyridine (4.96 gm, 40.6 mmole) in dry CH₂Cl₂ (40 mL) under an atmosphere of dry nitrogen was cooled in an ice bath. Trifluoromethanesulfonic anhydride (3.76 mL, 22.3 mmol) was slowly added with stirring and a white precipitate formed. The reaction was removed from the bath after 20 min and was left stirring at room temperature for 45 min. It was then partitioned between water and a mixture of EtOAc : hexane = 3:2. The organic phase was removed and washed with water (3 times), brine and dried (Na₂SO₄). Removal of the solvent followed by silica gel column chromatography (elution with 500 mL portions of hexane containing 100, 125, 150, 175 (twice) mL of EtOAc) afforded 21.9 gm (98% yield) of 2'-O-(t-butyldimethylsilyl)-7-O-trifluoromethanesulfonylpaclitaxel: ¹H NMR (CDCl₃) δ -0.32 (s, 3H), -0.04 (s, 3H), 0.77 (s, 9H), 1.16 (s, 3H), 1.20 (s, 3H), 1.87 (s, 3H), 2.05 (s, 3H), 2.17 (s, 3H), 2.58 (s, 3H), 2.0 - 2.4 (m, 3H), 2.85 (m, 1H), 3.95 (d, 1H, J = 6.9 Hz), 4.20 (d, 1H, J = 8.5 Hz), 4.35 (d, 1H, J = 8.5 Hz), 4.64 (d, 1H, J = 2.1 Hz), 4.92 (d, 1H, J = 8.7 Hz), 5.47 (dd, 1H, J = 7.5, 10.2 Hz), 5.73 (m, 2H), 6.24 (m, 1H), 6.60 (s, 1H), 7.04 (d, 1H, J = 9.0 Hz) 7.3 - 8.1 (m, 15 H).


Example 1

A solution of 2'-O-(t-butyldimethylsilyl)-7 β -O-trifluoromethanesulfonylpaclitaxel (3a) (240 mg, 0.237 mmole) in 2 mL of dry dimethylformamide was cooled in an acetone/ice bath at about -10°C under a dry nitrogen atmosphere. Powdered lithium thiomethoxide (Prepared by the method of T.R. Kelly et al., Tetrahedron Letters, 1977, 3859) (30 mg, 2.5 equiv) were added and the reaction was then left stirring for 2 hr while maintaining the bath temperature below 0°C. The reaction was then quenched by adding a saturated solution of NH₄Cl with vigorous stirring. After

partitioning the resulting mixture between EtOAc and water, the organic phase was separated and washed with water (3 times), brine and dried (Na₂SO₄). Removal of the solvents was followed by chromatography on a silica gel preparative tlc plate (2 mm, developed 3 times with a mixture of EtOAc : hexane = 1 : 3) to afford 82 mg (38%) of 2'-O-(t-butyldimethylsilyl)-7-deoxy-7 α -thiomethylpaclitaxel (**4a**):

¹H NMR (CDCl₃) δ -0.36 (s, 3H), -0.07 (s, 3H), 0.76 (s, 9H), 1.18 (s, 3H), 1.16 (s, 3H), 1.62 (s, 3H), 1.81 (s, 3H), 2.02 (s, 3H), 2.2-2.7 (m, 5H), 2.10 (s, 3H), 2.58 (s, 3H), 4.01 (d, 1H, J = 7.0 Hz), 4.32 (d, 1H, J = 8.3 Hz), 4.62 (d, 1H, J = 8.3 Hz), 4.66 (d, 1H, J = 1.7 Hz), 5.00 (m, 1H), 5.70 (d, 1H, J = 7.0 Hz), 5.78 (d, 1H, J = 9.7 Hz), 6.27 (m, 1H), 7.08 (d, 1H, J = 9.0 Hz), 7.26 - 7.61 (m, 12H), 7.74 (d, 2H, J = 7.3 Hz), 8.13 (d, 2H, J = 7.0 Hz); LRMS (ESI) 998 ([M+H]⁺).

Example 2




A solution of 2'-O-(t-butyldimethylsilyl)-7-deoxy-7 α -thiomethylpaclitaxel (**4a**) (195 mg, 0.195 mmole) in dry THF (2 mL) and under a dry nitrogen atmosphere was cooled in an acetone/ice bath at about -10°C. A solution of tetrabutylammonium fluoride (0.22 mL, 1.0 M in THF, 1.1 equiv) was added. After 20 min, the reaction was quenched by adding a saturated solution of NH₄Cl with vigorous stirring. This was extracted with EtOAc (3 times) and the combined organic extracts were washed with brine and dried (Na₂SO₄). Removal of the solvents was followed by chromatography on a silica gel preparative tlc plate (2 mm, developed 3 times with a mixture of EtOAc : hexane = 3 : 2) to afford 140 mg (81%) of 7-deoxy-7 α -thiomethylpaclitaxel (**5a**):

¹H NMR (CDCl₃) δ 1.16 (s, 3H), 1.17 (s, 3H), 1.80 (s, 3H), 1.88 (s, 3H), 2.09 (s, 3H), 2.18 (s, 3H), 2.3 - 2.6 (m, 5H), 2.41 (s, 3H), 3.42 (d, 1H, J = 4.6 Hz), 4.00 (d, 1H, J = 7.0 Hz), 4.28 (d, 1H, J = 8.2 Hz), 4.61 (d, 1H, J = 4.6 Hz), 4.79 (dd, 1H, J =

2.4, 4.6 Hz), 4.95 (m, 1H), 5.69 (d, 1H, $J = 7.0$ Hz), 5.84 (dd, 1H, $J = 1.9, 9.5$ Hz), 5.82 (m, 1H), 7.01 (d, 1H, $J = 9.2$ Hz), 7.19 (s, 1H), 7.32 - 7.62 (m, 11H), 7.74 (d, 2H, $J = 7.7$ Hz), 8.13 (d, 2H, $J = 7.7$ Hz); LRMS (negative ESI) 882 ($[M-H]^-$).


5

Example 3

A solution of 2'-O-(t-butyldimethylsilyl)-7-deoxy-7 α -thiomethylpaclitaxel (4a) (446 mg, 0.447 mmole) in CH_2Cl_2 (4 mL) was cooled in an ice bath and solid m-chloroperbenzoic acid (0.238 gm, 80%, 2.5 equiv) was added. The reaction was removed from the bath and left stirring at rt for 1.5 hr. It was then diluted with EtOAc and washed with: 10% aqueous solution of $NaHSO_3$; saturated aqueous $NaHCO_3$ solution (4 times); brine; and then dried (Na_2SO_4). Removal of the solvents followed by chromatography on two silica gel preparative tlc plates (2 mm, developed 3 times with a mixture of EtOAc : hexane = 30 : 70) to afford 288 mg (63%) of 2'-O-(t-butyldimethylsilyl)-7-deoxy-7 α -methylsulfonylpaclitaxel (6a):

1H NMR ($CDCl_3$) δ -0.36 (s, 3H), -0.07 (s, 3H) 0.76 (s, 9H), 1.18 (s, 3H), 1.22 (s, 3H), 1.96 (s, 3H), 2.01 (s, 3H), 2.17 (s, 3H), 2.56 (s, 3H), 2.1 - 2.8 (m, 4H), 2.95 (s, 3H), 3.65 (m, 1H), 4.13 (d, 1H, $J = 6.8$ Hz), 4.52 (d, 1H, $J = 8.6$ Hz), 4.57 (d, 1H, $J = 8.6$ Hz), 4.64 (d, 1H, $J = 1.7$ Hz), 5.36 (m, 1H), 5.77 (m, 2H), 6.28 (m, 1H), 7.08 (d, 1H, $J = 9.1$ Hz), 7.23 (s, 1H), 7.3 - 7.6 (m, 12H), 7.74 (d, 2H, $J = 7.1$ Hz), 8.08 (d, 2H, $J = 7.1$ Hz); LRMS (negative ESI) 1028 ($[M-H]^-$); IR (KBr disk) 1315 cm^{-1} .


30

Example 4

- 5 A solution of 2'-O-(t-butyldimethylsilyl)-7-deoxy-7 α -methylsulfonylpaclitaxel (**6a**) (130 mg, 0.126 mmole) in dry THF (1 mL) and under a dry nitrogen atmosphere was cooled in an acetone/ice bath at about -10°C. A solution of tetrabutylammonium fluoride (0.14 mL, 1.0 M in THF, 1.1 equiv) was added. After 20 min, the reaction was quenched by
- 10 adding a saturated solution of NH₄Cl with vigorous stirring. This was extracted with EtOAc (3 times) and the combined organic extracts were washed with brine and dried (Na₂SO₄). Removal of the solvents was followed by chromatography on a silica gel preparative tlc plate (2 mm, developed 2 times with a mixture of EtOAc : hexane = 3 : 1) to afford 77 mg
- 15 (67%) of 7-deoxy-7 α -methylsulfonylpaclitaxel (**7a**):

¹H NMR (CDCl₃) δ 1.17 (s, 3H), 1.22 (s, 3H), 1.88 (s, 3H), 1.92 (s, 3H), 2.17 (s, 3H), 2.40 (s, 3H), 2.2 - 2.7 (m, 4H), 2.94 (s, 3H), 3.63 (m, 1H), 4.14 (d, 1H, J = 6.4 Hz), 4.5 (br s, 1H), 4.54 (d, 1H, J = 8.5 Hz), 4.46 (d, 1H, J = 8.5 Hz), 4.78 (d, 1H, J = 1.8 Hz), 5.29 (m, 1H), 5.78 (d, 1H, J = 6.4 Hz), 5.84 (dd, 1H, J = 1.8, 9.2 Hz), 6.20 (m, 1H), 7.04 (d, 1H, J = 9.2 Hz), 7.16 (s, 1H), 7.2 - 7.6 (m, 11H), 7.74 (d, 2H, J = 7.8 Hz), 8.09 (d, 2H, J = 7.8 Hz); LRMS (negative ESI) 914 ([M-H]⁻); IR (KBr disk) 1315 cm⁻¹.


25

Example 5

A solution of 2'-O-(t-butyldimethylsilyl)-7-deoxy-7 α -methylsulfonylpaclitaxel (**6a**) (155 mg, 0.151 mmole) in dry THF (1.5 mL) under a nitrogen atmosphere was cooled to -78°C and a solution of LiHMDSA (0.30 mL, 1.0 M in THF, 2 equiv) was added dropwise. A thick gel forms within 10 min and the reaction was removed from the bath. After 15 min the gel had turned into a liquid and a saturated solution of NH₄Cl was added with vigorous stirring. This mixture was extracted with EtOAc and the extract was washed with brine and dried (Na₂SO₄). Removal of the solvents was followed by chromatography on a silica gel preparative tlc plate (2 mm, developed 2 times with a mixture of EtOAc : hexane = 1 : 1) to afford 91 mg (61%) of the desired product (**8a**):

¹H NMR (CDCl₃) δ -0.39 (s, 3H), -0.02 (s, 3H), 0.76 (s, 9H), 1.24 (s, 3H), 1.70 (s, 3H), 1.83 (s, 3H), 1.97 (s, 3H), 2.12 (s, 3H), 2.1 - 2.5 (m, 3H), 2.54 (s, 3H), 2.68 (t, 1H, J = 13.6 Hz), 3.16 (d, 1H, J = 14.0 Hz), 3.37 (s, 1H), 3.40 (d, 1H, J = 14.2 Hz), 3.57 (d, 1H, J = 3.6 Hz), 3.77 (dd, 1H, J = 6.2, 13.4 Hz), 4.20 (d, 1H, J = 7.9 Hz), 4.51 (d, 1H, J = 7.9 Hz), 4.69 (d, 1H, J = 1.7 Hz), 5.32 (d, 1H, J = 3.5 Hz), 5.77 (d, 1H, J = 9.0 Hz), 6.10 (d, 1H, J = 3.8 Hz), 6.28 (m, 1H), 6.77 (s, 1H), 7.09 (d, 1H, J = 9.0 Hz), 7.3 - 7.8 (m, 11H), 7.76 (m, 2H), 8.07 (m, 2H).

Example 6




A solution of the 2'-O-(t-butyldimethylsilyl)-derivative (**8a**) (94 mg, 0.091 mmole) in dry THF (1 mL) and under a dry nitrogen atmosphere was cooled in an acetone/ice bath at about -10°C. A solution of tetrabutylammonium fluoride (0.10 mL, 1.0 M in THF, 1.1 equiv) was added. After 5 min, the reaction was quenched by adding a saturated solution of NH₄Cl with vigorous stirring. This was extracted with EtOAc (3 times) and the combined organic extracts were washed with brine and dried (Na₂SO₄). Removal of the solvents was followed by chromatography on a silica gel preparative tlc plate (2 mm, developed

with a mixture of EtOAc : hexane = 65 : 35) to afford 63 mg (76%) of the desired product (9a):


¹H NMR (CDCl₃) δ 1.09 (s, 3H), 1.59 (s, 3H), 1.69 (s, 3H), 1.72 (s, 3H), 2.01 (s, 3H), 2.21 (s, 3H), 2.0 - 2.4 (m, 3H), 2.54 (m, 1H), 3.07 (d, 1H, J = 14.1 Hz), 3.31 (d, 1H, J = 14.1 Hz), 3.40 (s, 1H), 3.48 (d, 1H, J = 3.5 Hz), 3.65 (dd, 1H, J = 6.2, 13.2 Hz), 4.11 (d, 1H, J = 8.0 Hz), 4.41 (d, 1H, J = 8.0 Hz), 4.63 (m, 1H), 4.73 (s, 1H), 5.14 (d, 1H, J = 3.5 Hz), 5.78 (d, 1H, J = 7.8 Hz), 6.06 (m, 1H), 6.57 (s, 1H), 7.3 - 7.8 (m, 12H), 7.81 (m, 2H), 8.05 (m, 2H); LRMS (ESI) 916 ([M+H]⁺).

10


Example 7



Potassium thioacetate (7.30 gm, 10 equiv) was added to a stirred solution of 2'-O-(t-butyldimethylsilyl)-7β-O-trifluoromethanesulfonyl-paclitaxel (3a) (7.07 g, 6.40 mmole) in 64 mL of absolute EtOH at room temperature under a dry nitrogen atmosphere. After stirring for 45 hr in the dark, the reaction was partitioned between a mixture of EtOAc : hexane = 1 : 1 and water, the organic phase was separated and washed with water (2 times), brine and dried (Na₂SO₄). Removal of the solvents was followed by chromatography on a silica gel column (gradient elution with mixtures of EtOAc : hexane = 1 : 4 to 7 : 13) to afford 5.82 gm (89%) of 2'-O-(t-butyldimethylsilyl)-7-deoxy-7α-thioacetoxypaclitaxel (10a): ¹H NMR (CDCl₃) δ -0.33 (s, 3H), -0.05 (s, 3H), 0.78 (s, 9H), 1.12 (s, 3H), 1.17 (s, 3H), 1.8 - 2.4 (m, 4H), 2.04 (s, 3H), 2.13 (s, 3H), 2.43 (s, 3H), 2.63 (s, 3H), 3.89 (d, 1H, J = 7.0 Hz), 4.00 (m, 1H), 4.28 (d, 1H, J = 8.3 Hz), 4.64 (d, 1H, J = 8.4 Hz), 4.68 (d, 1H, J = 1.9 Hz), 4.85 (m, 1H), 5.69 (d, 1H, J = 7.0 Hz), 5.80 (br d, 1H, J = 8.5 Hz), 6.29 (m, 1H), 6.89 (s, 1H), 7.06 (d, 1H, J = 9.0 Hz), 7.3 - 7.6 (m, 11H), 7.74 (m, 2H), 8.15 (m, 2H); LRMS (ESI) 1026 ([M+H]⁺).

Example 8

A solution of 2'-O-(t-butyldimethylsilyl)-7-deoxy-7 α -thioacetoxypaclitaxel (10a) (0.96 gm, 0.94 mmole) in anhydrous EtOH (50 mL) was sparged with dry nitrogen for 45 min. This solution was then saturated with anhydrous NH₃ and then left stirring at room temperature for 1hr. It was sparged with dry nitrogen for 20 min and the solvent was removed. The residue was chromatographed on a silica gel column (elution with 200 mL portions of hexane containing 50, 60, 70, 80 (twice) mL of EtOAc) to afford 0.57 gm (61%) of slightly impure 2'-O-(t-butyldimethylsilyl)-7-deoxy-7 α -thiopaclitaxel (12a): ¹H NMR (CDCl₃) δ -0.34 (s, 3H), -0.07 (s, 3H), 0.76 (s, 9H), 1.15 (s, 3H), 1.18 (s, 3H), 1.84 (s, 3H), 1.97 (s, 3H), 2.1 - 2.6 (m, 4H), 2.17 (s, 3H), 2.63 (s, 3H), 2.93 (m, 1H), 3.70 (d, 1H, J = 13.0 Hz), 4.06 (d, 1H, J = 7.1 Hz), 4.26 (d, 1H, J = 8.4 Hz), 4.67 (m, 2H), 4.95 (m, 1H), 5.71 (d, 1H, J = 6.8 Hz), 5.78 (d, 1H, J = 8.9 Hz), 6.28 (m, 1H), 7.07 (d, 1H, J = 8.9 Hz), 7.2 - 7.6 (m, 12 Hz), 7.74 (d, 2H, J = 7.4 Hz), 8.15 (d, 2H, J = 7.9 Hz); LRMS (ESI) 984 ([M+H]⁺).


Example 9

A solution of 2'-O-(t-butyldimethylsilyl)-7-deoxy-7 α -thiopaclitaxel (12a) (500 mg, 0.508 mmole) in dry toluene (20 mL) at room temperature was sparged with dry nitrogen for 20 min. 1,8-Diazabicyclo[5.4.0]undec-7-ene (0.152 mL, 2 equiv) was added and the reaction was placed in an oil bath at approximately 95°C. The isomerization of the starting material into its 7 β -

isomer was monitored by HPLC (Vydac 218TP reverse phase column, gradient elution: 75% aqueous CH₃CN to 100% CH₃CN over 9 min at 2 mL per min). After 18.5 hr, the ratio of 7 α to 7 β -thiol isomers was about 1 : 9 and the reaction was allowed to cool to room temperature and diluted with a mixture of EtOAc : hexane = 3 : 2. This was washed with saturated aqueous NH₄Cl (twice), brine, and then dried (Na₂SO₄). Removal of the solvents followed by radial chromatography (1 mm silica gel plate, gradient elution with mixtures of EtOAc : hexane = 1 : 4 to 7 : 13) afforded 344 mg (69%) of 2'-O-(t-butyldimethylsilyl)-7-deoxy-7 β -thiopaclitaxel (**13a**):

¹H NMR (CDCl₃) δ -0.31 (s, 3H), -0.05 (s, 3H), 0.79 (s, 9H), 1.17 (s, 3H), 1.20 (s, 3H), 1.69 (s, 3H), 1.8 - 2.2 (m, 3H), 1.91 (s, 3H), 2.40 (dd, 1H, J = 9.3, 15.3 Hz), 2.21 (s, 3H), 2.56 (s, 3H), 2.68 (m, 1H), 3.84 (d, 1H, J = 6.7 Hz), 4.17 (d, 1H, J = 8.4 Hz), 4.32 (d, 1H, J = 8.4 Hz), 4.65 (d, 1H, J = 2.1 Hz), 4.94 (d, 1H, J = 9.3 Hz), 5.69 (m, 2H), 6.23 (m, 1H), 6.28 (s, 1H), 7.05 (d, 1H, J = 8.8 Hz), 7.3 - 7.6 (m, 11H), 7.73 (d, 2H, J = 7.2 Hz), 8.11 (d, 2H, J = 7.2 Hz); LRMS (ESI) 984 ([M+H]⁺).


Example 10



A solution of 2'-O-(t-butyldimethylsilyl)-7-deoxy-7 β -thiopaclitaxel (**13a**) (234 mg, 0.238 mmole) in dry THF (3 mL) and under a dry nitrogen atmosphere was cooled in an ice bath. A solution of tetrabutylammonium fluoride (0.26 mL, 1.0 M in THF, 1.1 equiv) was added. After 5 min, the reaction was quenched by adding a saturated solution of NH₄Cl with vigorous stirring. This was extracted with EtOAc (2 times) and the combined organic extracts were washed with brine and dried (Na₂SO₄). Removal of the solvents was followed by column chromatography on silica gel (elution with 100 mL portions of hexane containing 30, 35, 40, 45, 50, 55 mL of EtOAc) to afford 115 mg (56%) of 7-deoxy-7 β -thiomethylpaclitaxel (**14a**): ¹H NMR (CDCl₃) δ 1.19 (s, 3H), 1.18 (s, 3H), 1.69 (s, 3H), 1.76 (s, 3H), 1.8 - 2.3 (m, 4H), 2.21 (s, 3H), 2.36 (s,

3H), 2.66 (m, 1H), 3.53 (m, 1H), 3.61 (br s, 1H), 3.79 (d, 1H, J = 6.6 Hz), 4.15 (d, 1H, J = 8.4 Hz), 4.29 (d, 1H, J = 8.4 Hz), 4.77 (br s, 1H), 4.90 (d, 1H, J = 8.8 Hz), 5.67 (d, 1H, J = 6.6 Hz), 5.78 (br d, 1H, J = 8.1 Hz), 6.16 (m, 1H), 6.24 (s, 1H), 7.02 (d, 1H, J = 8.8 Hz), 7.2 - 7.6 (m, 11H), 7.74 (d, 2H, J = 8.0 Hz), 8.09 (d, 2H, J = 8.0 Hz); LRMS (negative ESI) 868 ([M-H]⁻).


Example 11




10

Bromomethyl methyl ether (0.006 mL, 1.1 equiv) was added to a solution of 2'-O-(t-butyldimethylsilyl)-7-deoxy-7β-thiopaclitaxel (**13a**) (61 mg, 0.062 mmole) and 1,8-diazabicyclo[5.4.0]undec-7-ene (0.152 mL, 1.5 equiv) in dry CH₂Cl₂ (1 mL) and under a dry nitrogen atmosphere. After 10 min, the reaction was diluted with a mixture of EtOAc : hexane = 3 : 2. It was then washed with saturated aqueous NH₄Cl (twice), brine, and dried (Na₂SO₄). Removal of the solvents was followed by radial chromatography (1 mm silica gel plate, gradient elution with mixtures of EtOAc : hexane = 1 : 4 to 7 : 13) to afford 43 mg (67%) of 2'-O-(t-butyldimethylsilyl)-7-deoxy-7β-thiomethoxymethylpaclitaxel (**15a**): ¹H NMR (CDCl₃) δ -0.32 (s, 3H), -0.04 (s, 3H), 0.78 (s, 9H), 1.17 (s, 3H), 1.22 (s, 3H), 1.73 (s, 3H), 2.0 - 2.4 (m, 3H), 2.01 (s, 3H), 2.18 (s, 3H), 2.56 (s, 3H), 2.84 (m, 1H), 3.34 (s, 3H), 3.37 (m, 1H), 3.89 (d, 1H, J = 6.7 Hz), 4.18 (d, 1H, J = 8.5 Hz), 4.34 (d, 1H, J = 8.5 Hz), 4.62 (d, 1H, J = 11.9 Hz), 4.65 (d, 1H, J = 1.8 Hz), 4.70 (d, 1H, J = 11.9 Hz), 4.96 (d, 1H, J = 8.3 Hz), 5.66 (d, 1H, J = 6.7 Hz), 5.72 (d, 1H, J = 8.9 Hz), 6.24 (m, 1H), 6.49 (s, 1H), 7.06 (d, 1H, J = 8.9 Hz), 7.3 - 7.6 (m, 11H), 7.73 (d, 2H, J = 7.9 Hz), 8.11 (d, 2H, J = 7.9 Hz); LRMS (ESI) 1028 ([M+H]⁺).

30


Example 12

A solution of tetrabutylammonium fluoride (0.57 mL, 1.0 M in THF, 1.1 equiv) was added to a solution of (15a) 2'-O-(t-butyldimethylsilyl)-7-deoxy-7β-thiomethoxymethyl paclitaxel (511 mg, 0.516 mmole) in dry THF (5 mL) that was in an ice bath and maintained under a dry nitrogen atmosphere. After 5 min, the reaction was quenched by adding a saturated solution of NH₄Cl with vigorous stirring. This was extracted with EtOAc (3 times) and the combined organic extracts were washed with brine and dried (Na₂SO₄). Removal of the solvents was followed by column chromatography on silica gel (elution with 100 mL portions of hexane containing 30, 35, 40, 45, 50, 55, 60 mL of EtOAc) to afford 365 mg (77%) of 7-deoxy-7β-thiomethoxymethyl paclitaxel (16a): ¹H NMR (CDCl₃) δ 1.16 (s, 3H), 1.22 (s, 3H), 1.56 (s, 3H), 1.85 (s, 3H), 2.18 (s, 3H), 2.0 - 2.4 (m, 3H), 2.35 (s, 3H), 2.82 (m, 1H), 3.31 (m, 1H), 3.32 (s, 1H), 3.66 (d, 1H, J = 4.6 Hz), 3.82 (d, 1H, J = 6.5 Hz), 4.15 (d, 1H, J = 8.3 Hz), 4.30 (d, 1H, J = 8.3 Hz), 4.58 (d, 1H, J = 11.9 Hz), 4.70 (d, 1H, J = 11.9 Hz), 4.77 (dd, 1H, J = 2.6, 4.6 Hz), 4.92 (d, 1H, J = 9.3 Hz), 5.62 (d, 1H, J = 6.7 Hz), 5.79 (m, 1H), 6.15 (m, 1H), 6.46 (s, 1H), 7.07 (d, 1H; J = 8.9 Hz), 7.3 - 7.6 (m, 11H), 7.76 (m, 2H), 8.08 (d, 2H); LRMS (ESI) 914 ([M+H]⁺).

Example 13

Iodomethane (0.100 mL, 1.1 equiv) was added to a solution of 7-deoxy-7 β -thiopaclitaxel (**14a**) (1.30 gm, 1.49 mmole) and 1,8-diazabicyclo[5.4.0]undec-7-ene (0.33 mL, 1.5 equiv) in dry CH₂Cl₂ (14 mL) and under a dry nitrogen atmosphere. After 5 min, the reaction was diluted with CH₂Cl₂, washed with saturated aqueous NH₄Cl, water, and dried (Na₂SO₄). Removal of the solvents was followed by radial chromatography (2 mm silica gel plate, gradient elution with mixtures of EtOAc : hexane = 1 : 4 to 1 : 3) to afford 1.04 gm (79%) of 7-deoxy-7 β -thiomethylpaclitaxel (**18a**): ¹H NMR (CDCl₃) δ 1.16 (s, 3H), 1.21 (s, 3H), 1.70 (s, 3H), 1.84 (s, 3H), 2.09 - 2.27 (m, 3H), 2.12 (s, 3H), 2.19 (s, 1H), 2.35 (s, 3H), 2.73 (m, 1H), 3.04 (dd, 1H, J = 6.5, 11.8 Hz), 3.67 (m, 1H), 3.80 (d, 1H, J = 6.6 Hz), 4.14 (d, 1H, J = 8.4 Hz), 4.30 (d, 1H, J = 8.4 Hz), 4.77 (br s, 1H), 4.94 (d, 1H, J = 8.1 Hz), 5.61 (d, 1H, J = 6.6 Hz), 5.78 (dd, 1H, J = 2.4, 8.9 Hz), 6.14 (m, 1H), 6.53 (s, 1H), 7.07 (d, 1H, J = 8.9 Hz), 7.3 - 7.6 (m, 11H), 7.75 (d, 2H, J = 7.2 Hz), 8.08 (d, 2H, J = 7.2 Hz); LRMS (negative ESI) 882 ([M-H]⁻).


Example 14



1,8-Diazabicyclo[5.4.0]undec-7-ene (0.015 mL, 0.1 equiv) was added to a solution of 2'-O-(t-butyltrimethylsilyl)-7-deoxy-7 β -thiopaclitaxel (**13a**) (984 mg, 1.0 mmole) in dry benzene (25 mL) that had been saturated with ethylene oxide. After 5 hr, the solvent was removed and the residue was chromatographed (silica gel column; eluting with a mixture of EtOAc : hexane = 1 : 1) to afford 1.09 gm (99%) of O-(t-butyltrimethylsilyl)-7-deoxy-7 β -(hydroxyethylthio)-paclitaxel (**19a**). This was taken, dissolved in dry THF (10 mL), and cooled in an acetone/ice bath. Tetrabutylammonium fluoride (1.1 mL, 1.0 M in THF, 1.0 equiv) was added and after 5 min, the reaction was diluted with EtOAc and a solution of KHSO₄ (2 mL, 1.0 M) and water were added with stirring. The organic phase was separated, washed with brine, and dried (Na₂SO₄). Removal of the solvents was

followed by silica gel column chromatography (eluting with a mixtures of EtOAc : hexane : CH₂Cl₂ = 2 : 1 : 0.5) gave 610 mg (64%) of 7-deoxy-7 β -(2-hydroxyethylthio)-paclitaxel (**20a**): ¹H NMR (CDCl₃) δ 1.16 (br s, 9H), 1.74 (s, 3H), 1.83 (s, 3H) 1.85 (s, 3H), 2.15 - 2.4 (m, 3H), 2.23 (s, 3H), 2.36 (s, 3H), 2.64 - 2.82 (m, 3H), 3.26 (dd, 1H, J = 6.4, 11.6 Hz), 3.71 (m, 3H), 3.81 (d, 1H, J = 6.7 Hz), 4.17 (d, 1H, J = 8.4 Hz), 4.31 (d, 1H J = 8.4 Hz), 4.78 (br s, 1H), 4.91 (d, 1H, J = 7.9 Hz), 5.63 (d, 1H, J = 6.7 Hz), 5.77 (dd, 1H, J = 2.3, 8.9 Hz), 6.16 (m, 1H), 6.52 (s, 1H), 7.08 (d, 1H, J = 8.9 Hz), 7.51 - 8.09 (m, 15H); LRMS (ESI) 914 ([M+H]⁺).

Example 15




Tetrabutyl ammonium borohydride (682 mg, 2 equiv.) was added to a solution of 2'-O-(t-butyldimethylsilyl)-7-deoxy-7 β -thiomethylpaclitaxel (**18a**) (1.17 gm, 1.32 mmole) in a mixture of dry CH₂Cl₂ (127 mL) and MeOH (2.6 mL) under a nitrogen atmosphere at RT. After 7 hr, the reaction was quenched with saturated NH₄Cl solution and dried (Na₂SO₄). Removal of the solvents followed by radial chromatography (2 mm silica gel plate eluted with mixtures of EtOAc : hexane = 7 : 13 to 3 : 2) afforded 754 mg (93 %) of 7-deoxy-7 β -thiomethylbaccatin (**21a**): ¹H NMR (CDCl₃ + D₂O) δ 1.04 (s, 3H), 1.19 (s, 3H), 1.69 (s, 3H), 2.02 - 2.24 (m, 3H), 2.14 (s, 3H), 2.15 (s, 3H), 2.20 (m, 3H), 2.28 (s, 3H), 2.76 (m, 1H), 3.13 (dd, 1H, J = 8.5, 14.1 Hz), 3.90 (d, 1H, J = 6.7 Hz), 4.11 (d, 1H, J = 8.3 Hz), 4.31 (d, 1H, J = 8.3 Hz), 4.84 (m, 1H), 4.99 (d, 1H, J = 9.3 Hz), 5.57 (d, 1H, J = 6.7 Hz), 6.58 (s, 1H), 7.4 - 7.6 (m, 3H), 8.08 (d, 2H, J = 8.1 Hz); LRMS (negative ESI) 615 ([M-H]⁻). A solution of 7-deoxy-7 β -thiomethylbaccatin (**21a**) (482 mg, 0.782 mmole) in dry THF (15 mL) under dry N₂ was cooled to -50° C and a solution of lithium hexamethyldisilazide (1.0 M in THF, 0.94 mL, 1.2 equiv) was added. After 15 min, a solution of (3R, 4S)-1-(t-butoxycarbonyl)-4-phenyl-3-triethylsilyloxy-2-azetidinone (649 mg, 2.2

equiv) in dry THF (15 mL) was added by cannula and the reaction was transferred to an ice bath. After 45 min, this was quenched with a saturated NH_4Cl solution and extracted with mixture of EtOAc : hexane = 3 : 2. The organic extract was washed with brine and dried (Na_2SO_4).

- 5 Removal of the solvents followed by radial chromatography (2 mm silica gel plate eluted with mixtures of EtOAc : hexane = 1 : 4 to 7 : 13) afforded 740 mg (95%) of 2'-O-(triethylsilyl)-3'-NH-Boc-7-deoxy-7 β -thiomethylpaclitaxel (22a): ^1H NMR (CDCl_3) δ 0.37 (m, 6H), 0.77 (t, 9H), 1.23 (s, 6H), 1.32 (s, 9H), 1.71 (s, 3H), 2.00 (s, 3H), 2.07 - 2.39 (m, 3H), 2.14 (s, 3H), 2.21 (s, 3H), 2.52 (s, 3H), 2.76 (m, 1H), 3.12(dd, 1H, J = 6.3, 12.1 Hz), 3.88 (d, 1H, J = 6.8 Hz), 4.16 (d, 1H, J = 8.4 Hz), 4.33 (d, 1H, J = 8.4 Hz), 4.99 (d, 1H, J = 7.7 Hz), 5.27 (br d, 1H, J = 8.9 Hz), 5.47 (br d, 1H, J = 9.6 Hz), 5.65 (d, 1H, J = 6.8 Hz), 6.23 (m, 1H), 6.59 (s, 1H), 7.25 - 7.61 (m, 8H), 8.10 (m, 2H); LRMS (ESI) 994 ($[\text{M}+\text{H}]^+$). A solution of 2'-O-(triethylsilyl)-3'-NH-Boc-7-deoxy-7 β -thiomethylpaclitaxel (22a) (722 mg, 0.726 mmole) in acetonitrile (14 ml) was cooled in an ice bath and an aqueous solution of hydrochloric acid (1.45 mL, 1.0 N) was added. After 1.17 hr, this was neutralized by adding a saturated aqueous solution of NaHCO_3 and was then extracted with EtOAc. The organic extracts were washed with brine and dried (Na_2SO_4).
- 20 Removal of the solvents followed by radial chromatography (2 mm silica gel plate eluted with mixtures of EtOAc : hexane = 7 : 13 to 11 : 9) afforded 462 mg (72 %) of 3'-NH-Boc-7-deoxy-7 β -thiomethylpaclitaxel (23a): ^1H NMR (CDCl_3) 1.13 (s, 3H), 1.17 (s, 3H), 1.29 (s, 9H), 1.72 (s, 3H), 1.88 (s, 3H), 1.94 - 2.25 (m, 3H), 2.08 (s, 3H), 2.16 (s, 3H), 2.29 (s, 3H), 2.67 (m, 1H), 3.01 (dd, 1H, J = 6.4, 11.9 Hz), 3.46 (br s, 1H), 3.76 (d, 1H, J = 6.5 Hz), 4.08(d, 1H, J = 8.4 Hz), 4.25 (d, 1H, J = 8.4 Hz), 4.55 (br s, 1H), 4.89 (d, 1H, J = 7.8 Hz), 5.25 (br d, 1H, J = 8.7 Hz), 5.37 (br d, 1H, J = 9.4 Hz), 5.56 (d, 1H, J = 6.7 Hz), 6.09 (m, 1H), 6.51 (s, 1H), 7.22 - 7.57 (m, 8H), 8.02 (m, 2H); LRMS (ESI) 880 ($[\text{M}+\text{H}]^+$)


30

Example 16



- Ethyl iodide (0.057 mL, 1.1 equiv) was added to a solution of 2'-O-(t-butyldimethylsilyl)-7-deoxy-7 β -thiopaclitaxel (**13a**) (637 mg, 0.647 mmole) and 1,8-diazabicyclo[5.4.0]undec-7-ene (0.145 mL, 1.5 equiv) in dry CH₂Cl₂ (7 mL) at RT and under a N₂ atmosphere. After 30 min, the reaction was
- 5 treated with a saturated solution of NH₄Cl and diluted with CH₂Cl₂. The organic phase was separated, washed with water, and dried (Na₂SO₄). After the solvent was removed, the residue was dissolved in dry THF (6 mL), cooled in an acetone/ice bath, and tetrabutylammonium fluoride (0.71 mL, 1.0 M in THF, 1.1 equiv) was added. After 15 min, the reaction
- 10 was quenched by adding a saturated solution of NH₄Cl with vigorous stirring. This was extracted with EtOAc (3 times) and the combined organic extracts were washed with brine and dried Na₂SO₄. Removal of the solvents was followed by radial chromatography (2 mm silica gel plate, eluted with mixtures of EtOAc : hexane = 2 : 3 to 3 : 2) to afford 441 mg
- 15 (76%) of 7-deoxy-7 β -thioethylpaclitaxel (**24a**): ¹H NMR (CDCl₃) δ 1.16 (s, 3H), 1.22 (s, 3H), 1.67 (t, 3H, J = 7.4 Hz), 1.70 (s, 3H), 1.86 (s, 3H), 2.03 - 2.76 (m, 6H), 2.20 (s, 3H), 2.36 (s, 3H), 3.19 (dd, 1H, J = 6.5, 11.8 Hz), 3.69 (d, 1H, J = 4.8 Hz), 3.82 (d, 1H, J = 6.6 Hz), 4.16 (d, 1H, J = 8.4 Hz), 4.31 (d, 1H, J = 8.4 Hz), 4.78 (br s, 1H), 4.93 (d, 1H, J = 8.0 Hz), 5.62 (d, 1H, J = 6.6 Hz), 5.63 (d, 1H, J = 6.6 Hz), 5.78 (dd, 1H, J = 2.5, 8.9 Hz), 6.15 (m, 1H), 6.53 (s, 1H), 7.08 (d, 1H, J = 8.9 Hz), 7.31 - 7.63 (m, 11H), 7.75 (m, 2H), 8.09 (m, 2H); LRMS (ESI) 898 ([M+H]⁺).
- 20


25 Example 17



- Iodoacetone nitrile (0.047 mL, 1.1 equiv) was added to a solution of 7-deoxy-7 β -thiopaclitaxel (**14a**) (514 mg, 0.591 mmole) and 1,8-diazabicyclo[5.4.0]undec-7-ene (0.134 mL, 1.5 equiv) in dry CH₂Cl₂ (5 mL) and under a dry nitrogen atmosphere. After 10 min, the reaction was
- 30 diluted with CH₂Cl₂, washed with saturated aqueous NH₄Cl, water, and dried (Na₂SO₄). Removal of the solvents was followed by radial

chromatography (1 mm silica gel plate, gradient elution with mixtures of EtOAc : hexane = 7 : 13 to 13 : 7) afforded 389 mg (72%) of 7-deoxy-7 β -thiocyanomethylpaclitaxel (**25a**): IR (KBr disk) 2248 cm⁻¹; ¹H NMR (CDCl₃) δ 1.17 (s, 3H), 1.18 (s, 3H), 1.71 (s, 3H), 1.89 (s, 3H), 2.01 - 2.33 (m, 4H), 2.19 (s, 3H), 2.35 (s, 3H), 2.86 (m, 1H), 3.34 (d, 1H, J = 17.5 Hz), 3.42 (d, 1H, J = 17.5 Hz), 3.43 (m, 1H), 3.87 (d, 1H, J = 6.7 Hz), 4.14 (d, 1H, J = 8.5 Hz), 4.30 (d, 1H, J = 8.5 Hz), 4.77 (d, 1H, J = 2.3 Hz), 4.93 (d, 1H, J = 9.0 Hz), 5.63 (d, 1H, J = 6.7 Hz), 5.77 (dd, 1H, J = 2.0, 8.8 Hz), 6.15 (m, 1H), 6.47 (s, 1H), 7.07 (d, 1H, J = 8.8 Hz), 7.3 - 7.6 (m, 11H), 7.72 (d, 2H, J = 7.7 Hz), 8.08 (d, 2H, J = 7.7 Hz); LRMS (negative ESI) 907 ([M-H]⁻).


Example 18



A solution of 2'-O-(t-butyltrimethylsilyl)-7-deoxy-7 β -thiopaclitaxel (**13a**) (883 mg, 0.836 mmole) in dry toluene (25 mL) was sparged with dry nitrogen for 20 min. 1,8-Diazabicyclo[5.4.0]undec-7-ene (0.187 mL, 1.5 equiv) followed by phenyl vinylsulfoxide (0.117 mL) were added and the solution was left stirring at RT for 6 hr. The reaction was then maintained in a 120°C oil bath for 22hr. After cooling to RT, the reaction was diluted with EtOAc, washed with saturated NH₄Cl solution, brine, and then dried (Na₂SO₄). Radial chromatography (2 mm silica gel plate eluted with mixtures of EtOAc : hexane = 1 : 4 to 1 : 3) afforded 679 mg (about 80%) of impure 2'-O-(t-butyltrimethylsilyl)-7-deoxy-7 β -thiovinylpaclitaxel. This was dissolved in dry THF (3 mL) under dry nitrogen and cooled in an acetone/ice bath. A solution of tetrabutylammonium fluoride (0.74 mL, 1.0 M in THF, 1.1 equiv) was added and after 5 min, the reaction was quenched by adding a saturated solution of NH₄Cl with vigorous stirring. This was extracted with EtOAc (twice) and the combined organic extracts were washed with brine and dried (Na₂SO₄). Removal of the solvents followed by radial chromatography (2 mm silica gel plate eluted with mixtures of

EtOAc : hexane = 1 : 2 to 2 : 3) afforded 345 mg (46% overall) of 7-deoxy-7 β -thiovinylpaclitaxel (27a): ^1H NMR ($\text{CDCl}_3 + \text{D}_2\text{O}$) δ 1.17 (s, 3H), 1.21 (s, 3H), 1.72 (s, 3H), 1.85 (s, 3H), 2.1 - 2.3 (m, 3H), 2.18 (s, 3H), 2.37 (s, 3H), 2.75 (m, 1H), 3.44 (dd, 1H, J = 6.4, 12.0 Hz), 3.86 (d, 1H, J = 6.7 Hz), 4.16 (d, 1H, J = 8.4 Hz), 4.31 (d, 1H, J = 8.4 Hz), 4.78 (d, 1H, J = 2.4 Hz), 4.94 (d, 1H, J = 8.1 Hz), 5.27 (br s, 1H), 5.32 (d, 1H, J = 5.3 Hz), 5.64 (d, 1H, J = 6.7 Hz), 5.78 (dd, 1H, J = 9.8, 16.6 Hz), 6.44 (s, 1H), 7.08 (d, 1H, J = 8.9 Hz), 7.3 - 7.6 (m, 11H), 7.74 (d, 2H, J = 7.2 Hz), 8.09 (d, 2H, J = 87.2 Hz); LRMS (negative ESI) 894 ($[\text{M}-\text{H}]^-$).

10


Example 19

15 A solution of 2'-O-(t-butyltrimethylsilyl)-7-deoxy-7 β -thiopaclitaxel (13a) (664 mg, 0.675 mmole) and diisopropyl ethyl amine (0.141 mL, 1.2 equiv) in dry CH_2Cl_2 (10 mL) was added to a well-stirred solution of cyanogen bromide (357 mg, 5 equiv) in dry CH_2Cl_2 (10 mL) at RT over 3 min. After 15 min, the reaction was treated with an aqueous solution of Na_2SO_3 (10
20 %, 20 mL). The organic phase was separated, washed with water, and dried (Na_2SO_4). After the solvent was removed, the residue was dissolved in dry THF (6 mL) and cooled in an acetone/ice bath. A solution of tetrabutylammonium fluoride (0.74 mL, 1.0 M in THF, 1.1 equiv) was added. After 5 min, the reaction was quenched by adding a
25 saturated solution of NH_4Cl with vigorous stirring. This was extracted with EtOAc (3 times) and the combined organic extracts were washed with brine and dried Na_2SO_4 . Removal of the solvents was followed by radial chromatography (2 mm silica gel plate, eluted with mixtures of EtOAc : hexane = 8 : 12 to 11 : 9) to afford 433 mg (72%) of 7-deoxy-7 β -
30 thiocyanatopaclitaxel (28a): IR (KBr disk) 2155 cm^{-1} ; ^1H NMR (CDCl_3) δ 1.16 (s, 3H), 1.20 (s, 3H), 1.79 (s, 3H), 1.83 (s, 3H), 2.22 (s, 3H), 2.3 - 2.4 (m, 3H), 2.39 (s, 3H), 2.95 (m, 1H), 3.64 (d, 1H, J = 5.3 Hz), 3.78 (dd, 1H, J = 6.5, 11.9 Hz), 3.86 (d, 1H, J = 6.8 Hz), 4.17 (d, 1H, J = 8.5 Hz), 4.33 (d, 1H, J = 8.5 Hz), 4.79 (dd, 1H, J = 2.6, 5.2 Hz), 4.94 (d, 1H, J = 7.8 Hz), 5.66 (d, 1H, J = 6.8 Hz),

5.77 (dd, 1H, $J = 2.4, 8.9$ Hz), 6.18 (m, 1H), 6.36 (s, 1H), 7.00 (d, 1H, $J = 8.9$ Hz), 7.32 - 7.64 (m, 11H), 7.74 (d, 2H), 8.10 (d, 2H); LRMS (negative ESI) 893 ($[M-H]^-$).

5

Example 20




29a and 29b (both sulfoxide diastereomers)

- 10 Iodomethane (0.138 mL, 1.1 equiv) was added to a solution of 2'-O-(t-butylidimethylsilyl)-7-deoxy-7β-thiopaclitaxel (**13a**) (1.99 g, 2.02 mmole) and 1,8-diazabicyclo[5.4.0]undec-7-ene (0.459 mL, 1.5 equiv) in dry CH_2Cl_2 (20 mL) and under a dry nitrogen atmosphere. After 5 min, the reaction was diluted with EtOAc, washed with saturated aqueous NH_4Cl , water, and
- 15 dried (Na_2SO_4). The solvents were removed and the residue was dissolved in CH_2Cl_2 (20 mL) and cooled in an acetone/ice bath. A solution of m-chloroperbenzoic acid (435 mg, 80%, 1.05 equiv) in CH_2Cl_2 was added. After 30 min, some 10% aqueous Na_2SO_3 were added and the reaction was extracted with EtOAc. The organic phase was washed with
- 20 brine and dried (Na_2SO_4). The residue was chromatographed (radial chromatography, 4 mm silica gel plate, eluting with mixtures of EtOAc : hexane) to afford the 2 sulfoxide diastereomers of 2'-O-(t-butylidimethylsilyl)-7-deoxy-7β-methylsulfinyl-paclitaxel: a less polar isomer [527 mg; 1H NMR ($CDCl_3$) δ -0.30 (s, 3H), -0.06 (s, 3H), 0.79 (s, 9H),
- 25 1.18 (s, 3H), 1.21 (s, 3H), 1.81 (s, 3H), 1.86 (s, 3H), 2.12 - 2.65 (m, 4H), 2.21 (s, 3H), 2.49 (s, 3H), 2.58 (s, 3H), 2.89 (dd, 1H, $J = 7.6, 11.3$ Hz), 3.83 (d, 1H, $J = 6.6$ Hz), 4.15 (d, 1H, $J = 8.3$ Hz), 4.34 (d, 1H, $J = 8.3$ Hz), 4.64 (d, 1H, $J = 2.2$ Hz), 5.17 (d, 1H, $J = 7.9$ Hz), 5.70 (m, 2H), 6.23 (m, 1H), 6.28 (s, 1H), 7.06 (d, 1H, $J = 9.0$ Hz), 7.30 - 7.62 (m, 11H), 7.73 (d, 2H), 8.10 (d, 2H)] and a more polar
- 30 isomer [668 mg; 1H NMR ($CDCl_3$) δ -0.27 (s, 3H), 0.00 (s, 3H), 0.82 (s, 9H), 1.20 (s, 3H), 1.22 (s, 3H), 1.82 - 2.62 (m, 3H), 1.86 (s, 3H), 2.21 (s, 3H), 2.51 (s, 3H), 2.60 (s, 3H), 2.82 (m, 1H), 3.59 (dd, 1H, $J = 5.8, 12.9$ Hz), 3.97 (d, 1H, $J = 6.5$ Hz), 4.27 (d, 1H, $J = 8.2$ Hz), 4.39 (d, 1H, $J = 8.2$ Hz), 4.69 (d, 1H, $J = 2.1$ Hz),

5.13 (d, 1H, J = 7.8 Hz), 5.74 (m, 2H), 6.26 (m, 1H), 6.80 (s, 1H), 7.10 (d, 1H, J = 9.0 Hz), 7.31 - 7.64 (m, 11H), 7.76 (d, 2H), 8.15 (d, 2H)]. The t-butyltrimethylsilyl protecting groups were then removed from the individual sulfoxide diastereomers. For the less polar isomer this
5 involved dissolving the compound (509 mg, 0.503 mmole) in dry THF (5 mL), cooling this in an acetone ice bath, and then adding tetrabutylammonium fluoride (0.50 mL, 1.0 M in THF, 1.0 equiv). After 5 min, the reaction was diluted with EtOAc and a solution of KHSO₄ (1.4 mL, 1.0 M) was added with vigorous stirring. The organic phase was
10 washed with water (the aqueous washings were back-extracted with EtOAc), brine and dried (Na₂SO₄). Removal of the solvents was followed by radial chromatography (2 mm silica gel plate, eluted with mixtures of EtOAc : hexane = 4 : 1 to 100% EtOAc and then a mixture of 2.5% MeOH in EtOAc) to afford 351 mg (78%) of a sulfoxide diastereomer of 7-deoxy-7β-methylsulfinyl-paclitaxel (29a): ¹H NMR (CDCl₃) δ 1.17 (s, 3H), 1.20 (s, 3H), 1.68 (s, 3H), 1.72 (s, 3H), 2.22 (s, 3H), 2.24 - 2.63 (m, 6H), 2.39 (s, 3H), 2.46 (s, 3H), 2.85 (dd, 1H, J = 7.8, 11.0 Hz), 3.77 (d, 1H, J = 6.5 Hz), 4.10 (d, 1H, J = 8.3 Hz), 4.30 (d, 1H, J = 8.3 Hz), 4.75 (d, 1H, J = 2.7 Hz), 5.11 (d, 1H, J = 8.3 Hz), 5.66 (d, 1H, J = 6.5 Hz), 5.75 (dd, 1H, J = 2.6, 8.8 Hz), 6.16 (m, 1H), 6.24 (s, 1H),
20 7.12 (d, 1H, J = 8.8 Hz), 7.25 - 7.63 (m, 11H), 7.74 (m, 2H), 8.09 (m, 2H); LRMS (ESI) 900 ([M+H]⁺). Similar treatment of the more polar silyl ether (651 mg, 643 mmole) afforded 473 mg (82%) of the other sulfoxide diastereomer of 7-deoxy-7β-methylsulfinyl-paclitaxel (29b): ¹H NMR (CDCl₃) δ 1.12 (s, 3H), 1.16 (s, 3H), 1.86 (s, 3H), 1.76 - 2.48 (m, 6H), 1.94 (s, 3H), 2.16 (s, 3H), 2.38 (s, 3H), 2.43 (s, 3H), 2.68 (m, 3H), 3.50 (dd, 1H, J = 6.1, 12.7 Hz), 3.87 (d, 1H, J = 6.5 Hz), 4.20 (d, 1H, J = 8.5 Hz), 4.33 (d, 1H, J = 8.5 Hz), 4.79 (d, 1H, J = 2.6 Hz), 5.04 (d, 1H, J = 7.9 Hz), 5.67 (d, 1H, J = 6.8 Hz), 5.79 (dd, 1H, J = 2.4, 8.9 Hz), 6.17 (m, 1H), 6.75 (s, 1H), 7.13 (d, 1H, J = 9.0 Hz), 7.31 - 7.64 (m, 11H), 7.75 (m, 2H), 8.11 (m, 2H); LRMS (ESI) 900 ([M+H]⁺).

30


35

Example 21

- 5 1,8-Diazabicyclo[5.4.0]undec-7-ene (0.360 mL, 3 equiv) was added to an ice-cooled suspension of the hydrochloride salt of 2-picolyl chloride (145 mg, 1.1 equiv) and 2'-O-(t-butyltrimethylsilyl)-7-deoxy-7β-thiopaclitaxel (**13a**) (792 mg, 0.805 mmole) in dry THF (7 mL). After 5 min, the reaction was removed from the bath and allow to stir at RT for 30 min. It was then
- 10 diluted with 75% EtOAc in hexane and washed with saturated NH₄Cl solution, brine, and dried (Na₂SO₄). Radial chromatography (2 mm silica gel plate eluted with mixtures of EtOAc : hexane = 3 : 7 to 3 : 2) afforded 607 mg 2'-O-(t-butyltrimethylsilyl)-7-deoxy-7β-(thio-2-picolyl)-paclitaxel:
- 15 ¹H NMR (CDCl₃) δ -0.28 (s, 3H), 0.00 (s, 3H), 0.82 (s, 9H), 1.11 (s, 3H), 1.14 (s, 3H), 1.57 (s, 3H), 1.73 (s, 3H), 2.01 - 2.37 (m, 3H), 2.18 (s, 3H), 2.49 (s, 3H), 2.89 (m, 1H), 3.05 (dd, 1H, J = 6.3, 11.3 Hz), 3.68 (d, 1H, J = 6.7 Hz), 3.88 (d, 1H, J = 13.7 Hz), 3.93 (d, 1H, J = 13.7 Hz), 4.14 (d, 1H, J = 8.4 Hz), 4.30 (d, 1H J = 8.4 Hz), 4.61 (d, 1H, J = 1.8 Hz), 4.92 (d, 1H, J = 8.1 Hz), 5.63 (m, 2H), 6.10 (m, 1H), 6.22 (s, 1H), 7.04-8.45 (m, 20H). This silyl ether (589 mg, 0.548 mmole)
- 20 was dissolved in dry THF (6 mL) and cooled in an acetone/ice bath. Tetrabutylammonium fluoride (0.55 mL, 1.0 M in THF, 1.0 equiv) was added and after 5 min, water, and a solution of KHSO₄ (0.55 mL, 1.0 M) were added with stirring. This was washed with EtOAc (three times) and the combined organic phase were washed with brine and dried (Na₂SO₄).
- 25 Removal of the solvents was followed by radial chromatography (2 mm silica gel plate, eluted with mixtures of EtOAc : hexane = 1 : 1 to 4 : 1) to afford 447 mg (85%) of 7-deoxy-7β-(thio-2-picolyl)-paclitaxel (**30a**): ¹H NMR (CDCl₃) δ 1.12 (s, 3H), 1.18(s, 3H), 1.45 (s, 3H), 1.72 (s, 3H), 1.97 - 2.63 (m, 3H), 2.20 (s, 3H), 2.82 (m, 1H), 3.00 (dd, 1H, J = 6.7, 11.5 Hz), 3.64 (d, 1H, J = 6.7
- 30 Hz), 3.72 (d, 1H, J = 4.7 Hz), 3.83 (d, 1H, J = 13.8 Hz), 3.92 (d, 1H, J = 13.8 Hz), 4.12 (d, 1H, J = 8.5 Hz), 4.28 (d, 1H J = 8.5 Hz), 4.75 (dd, 1H, J = 2.8, 4.45 Hz), 4.86 (d, 1H, J = 8.0 Hz), 5.58 (d, 1H, J = 6.6 Hz), 5.76 (dd, 1H, J = 2.4, 8.9 Hz),

6.07 (m, 1H), 6.23 (s, 1H), 7.05 (d, 1H, $J = 8.9$ Hz), 7.10 - 8.51 (m, 19H); LRMS (ESI) 961 ($[M+H]^+$).

5 Example 22




31a and 31b (mixture of sulfoxide diastereomers)

Chloromethyl methylsulfide (0.435 mL, 3 equiv) was added to a solution of 2'-O-(*t*-butyldimethylsilyl)-7-deoxy-7 β -thiopaclitaxel (**14a**) (1.48 g, 1.50 mmole) and 1,8-diazabicyclo[5.4.0]undec-7-ene (0.912 mL, 4 equiv) in dry benzene (15 mL) and under a dry nitrogen atmosphere. After 5 min, the reaction was diluted with EtOAc, washed with saturated aqueous NH_4Cl , brine, and dried (Na_2SO_4). The solvents were removed and the residue was chromatographed (silica gel column chromatography; eluting with mixtures of EtOAc : hexane = 1 : 4 to 7 : 13) to afford 1.08 gm (70%) of O-(*t*-butyldimethylsilyl)-7-deoxy-7 β -thiomethylthiomethylpaclitaxel: ^1H NMR (CDCl_3) δ -0.28 (s, 3H), -0.00 (s, 3H), 0.82 (s, 9H), 1.25 (s, 3H), 1.21 (s, 3H), 1.80 (s, 3H), 2.06 - 2.48 (m, 3H), 2.08 (s, 3H), 2.21 (s, 3H), 2.23 (s, 3H), 2.61 (s, 3H), 2.81 (m, 1H), 2.54 (dd, 1H, $J = 6.4, 11.7$ Hz), 3.65 (d, 1H, $J = 14.3$ Hz), 3.74 (d, 1H, $J = 14.3$ Hz), 3.93 (d, 1H, $J = 6.8$ Hz), 4.23 (d, 1H, $J = 8.4$ Hz), 4.37 (d, 1H, $J = 8.4$ Hz), 4.70 (d, 1H, $J = 2.1$ Hz), 5.71 (d, 1H, $J = 6.8$ Hz), 5.76 (s, 1H, $J = 1.8, 8.9$ Hz), 6.2 (m, 1H), 6.52 (s, 1H), 7.09 (d, 1H, $J = 8.9$ Hz), 7.31 - 8.106 (m, 15H); LRMS (negative ESI) 1042 ($[M-H]^-$). A solution of *m*-chloroperbenzoic acid (203 mg, 80%, 1 equiv) in CH_2Cl_2 was added to a solution of O-(*t*-butyldimethylsilyl)-7-deoxy-7 β -thiomethylthiomethylpaclitaxel (983 mg, 0.942 mmole) in CH_2Cl_2 (15 mL) in an acetone/ice bath. After 20 min, some 10% aqueous Na_2SO_3 was added and the reaction was extracted with a mixture of EtOAc : hexane = 1 : 1. The organic phase was washed with saturated NaHCO_3 solution (three times), brine and dried (Na_2SO_4). Removal of the solvents left a white solid which was taken directly and dissolved in dry THF (8 mL). This was cooled in an acetone ice bath and tetrabutylammonium fluoride (0.50 mL, 1.0 M in THF, 1.0 equiv). After 15

min, the reaction was diluted with EtOAc and a solution of KHSO_4 (2 mL, 1.0 M) and water were added with stirring. The organic phase was separated, washed with brine, and dried (Na_2SO_4). Removal of the solvents was followed by silica gel column chromatography (eluting with mixtures of EtOAc : hexane = 1 : 1 to 100% EtOAc) to give 360 mg (40%) of an approximately 3 : 1 mixture of chromatographically homogeneous sulfoxide diastereomers of 7-deoxy-7 β -methylsulfinylmethylthiopaclitaxel (31a and 31b): ^1H NMR (CDCl_3) δ 1.11 - 2.91 (m, 25H), 3.46 - 4.22 (m, 6H), 4.71 (d, 1H, J = 2.8 Hz), 4.86 (br d, 1H, J = 7.8 Hz), 5.57 (d, 1H, J = 6.7 Hz), 5.71 (dd, 1H, J = 2.5, 8.5 Hz), 6.08 (m, 1H), 6.40 (s, 0.75H), 6.52 (s, 0.25H), 7.23 - 8.04 (m, 16H); LRMS (negative ESI) 944 ($[\text{M}-\text{H}]^-$).

Example 23



Methyl propiolate (0.159 mL, 1.5 equiv) was added to an ice cooled solution of 2'-O-(t-butyltrimethylsilyl)-7-deoxy-7 β -thiopaclitaxel (13a) (1.17g, 1.19 mmole) and 1,8-diazabicyclo[5.4.0]undec-7-ene (0.017 mL, 0.1 equiv) in dry CH_2Cl_2 (25 mL). After 30 min, the reaction was diluted with EtOAc and wash with saturated aqueous NH_4Cl , brine, and dried (Na_2SO_4). The solvents were removed and the residue was chromatographed (silica gel column; eluting with mixtures of EtOAc : hexane = 1 : 4 to 7 : 13) to separate the E and Z methyl acrylate isomers. This afforded 399 mg of a less polar isomer and 563 mg of a polar isomer of O-(t-butyltrimethylsilyl)-7-deoxy-7 β -thio-(3-methylacrylate)paclitaxel. The less polar isomer (390 mg, 0.366 mmole) was dissolved in dry THF (4 mL) and cooled in an acetone/ice bath. Tetrabutylammonium fluoride (0.36 mL, 1.0 M in THF, 1.0 equiv) was added and after 5 min, the reaction was diluted with EtOAc and a solution of KHSO_4 (0.73 mL, 1.0 M) and water were added with stirring. The organic phase was separated, washed with brine, and dried (Na_2SO_4). Removal of the solvents followed by silica gel column chromatography (eluting with a mixtures of EtOAc :

hexane : CH₂Cl₂ = 7 : 13 : 9 : 11) gave 210 mg (60%) of the E isomer of 7-deoxy-7 β -thio-(3-methylacrylate)paclitaxel (**34a**): ¹H NMR (CDCl₃) δ 1.12 (s, 3H), 1.14 (s, 3H), 1.70 (s, 3H) 1.79 (s, 3H), 2.12 (s, 3H), 2.04 - 2.28 (m, 3H), 2.33 (s, 3H), 2.36 (s, 3H), 2.70 (m, 1H), 3.26 (dd, 1H, J = 6.5, 12.1 Hz), 3.66 (s, 3H),
5 3.83 (d, 1H, J = 6.7 Hz), 4.11 (d, 1H, J = 8.5 Hz), 4.27 (d, 1H J = 8.5 Hz), 4.75 (d, 1H, J = 2.2 Hz), 4.88 (d, 1H, J = 7.9 Hz), 5.59 (d, 1H, J = 6.8 Hz), 5.73 (dd, 1H, J = 2.4, 8.9 Hz), 5.83 (d, 1H, J = 15.2 Hz), 6.11 (m, 1H), 6.29 (s, 1H), 7.02 (d, 1H, J = 8.9 Hz), 7.51 - 8.09 (m, 16H); LRMS (ESI) 952 ([M+H]⁺). Similar treatment of the more polar isomer (563 mg, 528 μ mole) afforded 357 mg (71%) of
10 the Z isomer of 7-deoxy-7 β -thio-(3-methylacrylate)paclitaxel (**35a**): ¹H NMR (CDCl₃) δ 1.11 (s, 3H), 1.15 (s, 3H), 1.64 (s, 3H) 1.70 (s, 3H), 1.80 (s, 3H), 2.09 (s, 3H) 2.14 - 2.36 (m, 3H), 2.32 (s, 3H), 2.60 (m, 1H), 3.21 (dd, 1H, J = 6.7, 12.0 Hz), 3.62 (m, 1H), 3.64 (s, 3H), 3.80 (d, 1H, J = 6.6 Hz), 4.10 (d, 1H, J = 8.5 Hz), 4.25 (d, 1H J = 8.5 Hz), 4.71 (dd, 1H, J = 2.4, 5.0 Hz), 4.86 (d, 1H, J = 7.7
15 Hz), 5.60 (d, 1H, J = 6.6 Hz), 5.72 (dd, 1H, J = 2.5, 8.9 Hz), 5.81 (d, 1H, J = 10.1 Hz), 6.10 (m, 1H), 6.35 (s, 1H), 6.86 (d, 1H, J = 10.1 Hz), 7.01 (d, 1H, J = 8.9 Hz), 7.27 - 8.05 (m, 15H); LRMS (negative ESI) 952 ([M-H]⁻)

The compounds of this invention exhibit antitumor activities in in vivo and/or in vitro models. For example, the following test describes the in vitro test used to evaluate some representative compounds of this invention.

Cytotoxicity (In-Vitro)

25

Cytotoxicity was assessed in HCT-116 human colon carcinoma cells by MTS (3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulphenyl)-2H-tetrazolium, inner salt) assay as reported in T.L. Riss, et. al., "Comparison of MTT, XTT, and a novel tetrazolium compound MTS for
30 in vitro proliferation and chemosensitivity assays," *Mol. Biol. Cell* 3 (Suppl.):184a, 1992. Cells were plated at 4,000 cell/well in 96 well microtiter plates and 24 hours later drugs were added and serial diluted. The cells were incubated at 37° for 72 hours at which time the tetrazolium dye, MTS at 333 μ g/ml (final concentration), in combination with the
35 electron coupling agent phenazine methosulfate at 25 μ M (final concentration) was added. A dehydrogenase enzyme in live cells reduces the MTS to a form that absorbs light at 492nm which can be quantitated spectrophotometrically. The greater the absorbance the greater the

number of live cells. The results are expressed as an IC_{50} , which is the drug concentration required to inhibit cell proliferation (i.e. absorbance at 450nm) to 50% of that of untreated control cells. The IC_{50} values for compounds evaluated in this assay are presented in Table II.

5

Table II.

Compound	IC_{50} (nM) HCT 116
5a (Example 2)	13.1
7a (Example 4)	72.3
9a (Example 6)	2.99
14a (Example 10)	13.5
16a (Example 12)	0.50
18a (Example 13)	0.20
20a (Example 14)	0.82
22a (Example 15)	0.30
24a (Example 16)	4.02
25a (Example 17)	<0.04
27a (Example 18)	1.2
28a (Example 19)	1.8
29a (Example 20)	3.99
29b (Example 20)	12.06
30a (Example 21)	1.12
31a&b (Example 22)	6.48
34a (Example 23)	6.97
35a (Example 23)	1.76
paclitaxel	1.71-2.28

Another aspect of the instant invention concerns a method for inhibiting human and/or other mammalian tumors which comprises administering to a tumor bearing host an antitumor effective amount of a compound of formula I.

For treating a variety of tumors, the compound of formula I of the present invention may be used in a manner similar to that of paclitaxel, e.g. see Physician's Desk Reference, 49th Edition, Medical Economics, p 682, 1995. The dosage, mode and schedule of administration for the compound of this invention are not particularly restricted; an oncologist

skilled in the art of cancer treatment will be able to ascertain, without undue experimentation, an appropriate treatment protocol for administering the compound of the present invention. Thus the compound of formula I may be administered via any suitable route of administration, parenterally or orally. Parenteral administration includes intravenous, intraperitoneal, intramuscular, and subcutaneous administration.

The doses utilized to implement the methods in accordance with the invention are the ones that make it possible to administer prophylactic treatment or to evoke a maximal therapeutic response. The doses vary, depending on the type of administration, the particular product selected, and the personal characteristics of the subject to be treated. In general, the doses are the ones that are therapeutically effective for the treatment of disorders caused by abnormal cell proliferation. The products in accordance with the invention can be administered as often as necessary in order to obtain the desired therapeutic effect. Some patients may respond rapidly to relatively high or low doses, and then require mild maintenance or no maintenance dose at all. Via the iv route, the dosage may be, for example, in the range of about 20 to about 500 mg/m² over 1 to 100 hours. Via the oral route, the dosage may be in the range of 5-1000mg/kg/day of body weight. The actual dose used will vary according to the particular composition formulated, the route of administration, and the particular site, host and type of tumor being treated. Many factors that modify the action of the drug will be taken into account in determining the dosage including age, weight, sex, diet and the physical condition of the patient.


The present invention also provides pharmaceutical formulations (compositions) containing an antitumor effective amount of compound of formula I in combination with one or more pharmaceutically acceptable carriers, excipients, diluents or adjuvants. The compositions can be prepared in accordance with conventional methods. Examples of formulating paclitaxel or derivatives thereof may be found in, for example, United States Patents Nos. 4,960,790 and 4,814,470, and such examples may be followed to formulate the compound of this invention. For example, compound of formula I may be formulated in the form of tablets, pills, powder mixtures, capsules, injectables, solutions,

suppositories, emulsions, dispersions, food premix, and in other suitable forms. It may also be manufactured in the form of sterile solid compositions, for example, freeze dried and, if desired, combined with other pharmaceutically acceptable excipients. Such solid compositions can
5 be reconstituted with sterile water, physiological saline, or a mixture of water and an organic solvent, such as propylene glycol, ethanol, and the like, or some other sterile injectable medium immediately before use for parenteral administration.

10 Typical of pharmaceutically acceptable carriers are, for example, manitol, urea, dextrans, lactose, potato and maize starches, magnesium stearate, talc, vegetable oils, polyalkylene glycols, ethyl cellulose, poly(vinylpyrrolidone), calcium carbonate, ethyl oleate, isopropyl myristate, benzyl benzoate, sodium carbonate, gelatin, potassium
15 carbonate, silicic acid. The pharmaceutical preparation may also contain nontoxic auxiliary substances such as emulsifying, preserving, wetting agents, and the like as for example, sorbitan monolaurate, triethanolamine oleate, polyoxyethylene monostearate, glyceryl tripalmitate, dioctyl sodium sulfosuccinate, and the like.

CLAIMSWhat is claimed is:

1. A compound of formula I, or a pharmaceutically acceptable salt thereof



I

- wherein R is hydrogen, C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, or -Z¹-R³;

Z¹ is a direct bond, C₁₋₆ alkyl, or -O-C₁₋₆ alkyl;

- R³ is aryl, substituted aryl, C₃₋₆ cycloalkyl, C₃₋₆ cycloalkenyl, cyclic 3-7 membered ring containing either one or two heteroatoms, or heteroaryl;

R^A is -NHC(O)R, -NHC(O)OR, -NHC(O)NHR, -NHC(O)N(R)₂, -NHS(O)_kR, -NHP(=O)(OR)₂ or -NHP=S(OR)₂, where k is 1 or 2;

- R^B is hydroxy, fluoro, -OC(O)R^x, -OC(O)OR^x, OP(O)(OH)₂, OCH₂OP(O)(OH)₂, -OCH₂OCH₂OP(=O)(OH)₂, OP(O)(OH)₂ base, OCH₂OP(O)(OH)₂ base, -OCH₂OCH₂OP(=O)(OH)₂ base, -(OCH₂)_mOC(=O)CH₂NHR^x, -(OCH₂)_mOC(=O)CH(R'')NR'₆R'₇, where m is 0-3, -OCOCH₂CH₂NH₃⁺ HCOO⁻, -OCOCH₂CH₂COOH, -OCO(CH₂)₃COOH, -OC(O)(CH₂)_nNR^FR^G, where n is 0-3, -OC(O)CH₂CH₂C(O)OCH₂CH₂OH or -OC(O)-Z-C(O)-R'; Z is ethylene (-CH₂CH₂-), propylene (-CH₂CH₂CH₂-), -CH=CH-, 1,2-cyclohexane or 1,2-phenylene;

R' is -OH, -OH base, -NR'₂R'₃, -OR'₃, -SR'₃, or -OCH₂C(O)NR'₄R'₅;

R'_2 is -H or -CH₃;

R'_3 is -(CH₂)_jNR'₆R'₇ or (CH₂)_nN⁺R'₆R'₇R'₈X⁻, where j is 1-3;

5 R'_4 is -H or -C₁-C₄ alkyl;

R'_5 is -H, -C₁-C₄ alkyl, benzyl, hydroxyethyl, -CH₂CO₂H or dimethylaminoethyl;

10 R'_6 and R'_7 are independently -H, -CH₃, -CH₂CH₃, benzyl or R'_6 and R'_7 together with the nitrogen of NR'₆R'₇ form a pyrrolidino, piperidino, morpholino, or N-methylpiperizino group;

R'_8 is -CH₃, -CH₂CH₃ or benzyl;

15

X⁻ is halide;

base is NH₃, (HOC₂H₄)₃N, N(CH₃)₃, CH₃N(C₂H₄)₂NH, NH₂(CH₂)₆NH₂, N-methylglucamine, NaOH or KOH;

20

R^F and R^G are independently -H or -C₁-C₃ alkyl, or R^F and R^G taken together with the nitrogen of NR^FR^G form a pyrrolidino, piperidino, morpholino or N-methylpiperizino groups;

25 R'' is -H, -CH₃, -CH₂CH(CH₃)₂, -CH(CH₃)CH₂CH₃, -CH(CH₃)₂, -CH₂phenyl, -(CH₂)₃NH₂, -(CH₂)₄NH₂, -CH₂CH₂COOH, -(CH₂)₃NHC(=NH)NH₂, the residue of the amino acid proline, -OC(O)CH=CH₂, -C(O)CH₂CH₂C(O)NHCH₂CH₂SO₃-Y⁺ or -OC(O)CH₂CH₂C(O)NHCH₂CH₂CH₂SO₃-Y⁺;

30

Y⁺ is Na⁺ or N⁺(Bu)₄;

R² is aryl or substituted aryl;

35 R^4 is -C₁₋₆ alkyl, -O-C₁₋₆ alkyl, or -C₃₋₆ cycloalkyl;

R⁶ and R^{6'} are independently hydrogen, hydroxy, C₁₋₆ alkyl, -SH, -S-R^W, halo, or together R⁶ and R^{6'} form a ketone;

- R^7 and $R^{7'}$ are independently hydrogen, mercapto, $-SR^W$, $-S(R^W)_2^+ K^-$, $-S(O)-R^W$, $-S(O)_2R^W$, $-S(O)_2OH$ and the corresponding salts, $-S(O)_2NHR^x$, $-S(O)_2N(R^x)_2$, $-S-S-R^W$, $-S-S-R^3$, $-S(CH_2)_aR^3$, where a is 0-4, $-S-CN$, $-S(O)-CN$, $-S(O)_2-CN$, $-SC(O)R^x$, $-SC(O)OR^x$, $-SC(S)R^x$, $-SC(S)SR^x$,
 5 $-SC(O)NHR^x$, $-SC(O)NR'_6R'^7$, $-SCH_2OR$, $-SC(R^x)_2OR$, $-SCHR^xOR$, $-SCH_2OCH_2OCH_3$, $-SCH_2SR$, $-SC(R^x)_2SR$, $-SCHR^xSR$, $-SCOCH_2CH_2NH_3^+ HCOO^-$, $-SCOCH_2CH_2COOH$, $-SCO(CH_2)_3COOH$, $-OC(O)(CH_2)_nNR^F R^G$, where n is 0-3, $-SC(O)-Z-C(O)-R'$, $-SC(O)CH_2CH_2C(O)OCH_2CH_2OH$, $-S(O)_bCH_2CN$, where b is 0-2, $-SCH_2C(O)C_{1-6}$ alkyl, $-SCH=C(X)(Y)$,
 10 $-S(CH_2)_rR^2$, where r is 1-4, or $-S(CH_2)_tS(O)_tC_{1-6}$ alkyl, where t is 0-2, with the proviso that both of R^7 and $R^{7'}$ cannot simultaneously be hydrogen;

X and Y are independently hydrogen, $COOR^a$, $C(O)R^a$, R^a , CN , aryl or heteroaryl, where R^a is C_{1-6} alkyl;

15

K is Br^- , Cl^- , I^- , $CH_3SO_3^-$, BF_4^- , CF_3COO^- , CH_3COO^- or $CF_3SO_2^-$;

- R^9 and $R^{9'}$ are independently hydrogen or hydroxy or together R^9 and $R^{9'}$ form a ketone; provided R^9 and $R^{9'}$ taken together can form part of a ring
 20 joined by $-CH_2S(O)_q-$ in which the carbon is attached at $R^{9'}$ and the sulfur at R^7 and where q is 0-2, R^9 is $-OH$, and R^7 is hydrogen; further provided R^9 and $R^{9'}$ taken together can form part of a ring joined by $=CHS(O)_q-$ in which the carbon is attached at R^9 and $R^{9'}$ to form a double bond and the sulfur at R^7 and where q is 0-2, and R^7 is hydrogen;

25

- R^{10} is hydrogen, hydroxy, $-OC(O)R^x$, $-OC(O)OR^x$, $-O-C_{1-6}$ alkyl, $-OCH_2OCH_3$, $-OCH_2OCH_2OCH_3$, $-OCH_2OCH_2OCH_2CH_3$, $-OCH_2OCH_2CH_2OCH_3$, $-OCH_2OCH_2CH_2OH$, $-OCH_2SR$, $-OCH_2OCH_2SCH_3$, $-OC(O)NR'_6R'^7$, C_{1-6} alkyl, $-(CH_2)_3C(O)R^x$,
 30 $-(CH_2)_3C(O)OR^x$, $-(CH_2)_3CN$, $-OP(O)(OH)_2$, $-OCH_2OP(O)(OH)_2$, $-OCH_2OCH_2OP(O)(OH)_2$, $-(OCH_2)_nOC=OCH_2NHR^x$, $-(OCH_2)_nOC(=O)CH(R'')NR'_6R'^7$, where n is 0-3, $-OCOCH_2CH_2NH_3^+ HCOO^-$, $-OCOCH_2CH_2COOH$, $-OCO(CH_2)_3COOH$, $-OC(O)-Z-C(O)-R'$, $-OC(O)(CH_2)_nNR^F R^G$ where n is 0-3, or $-OC(O)CH_2CH_2C(O)OCH_2CH_2OH$;

35

R^{19} is methyl or hydroxymethyl;

R^X is C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{3-6} cyclo alkyl, any of which groups can be optionally substituted with one to six of the same or different halogen atoms or with one or more hydroxy groups; and

- 5 R^W is C_{1-6} alkyl any of which groups can be optionally substituted with one to six of the same or different halogen atoms or with one or more hydroxy groups or with one or more carboxy groups or with one or more carboxy C_{1-6} alkyl esters or with one or more mercapto groups.

- 10 2. A compound of claim 1, wherein

R is 2-furanyl (2-furyl), 2-thienyl, 3-furanyl (3-furyl), 3-thienyl, phenyl, substituted phenyl, C_{3-6} alkyl, C_{3-6} alkenyl, C_{3-6} cycloalkyl or C_{3-6} cycloalkenyl;

15

R^A is $-NHC(O)Ph$, wherein Ph is substituted or unsubstituted, $-NHC(O)O(C_{1-6} \text{ alkyl})$, $-NHC(O)OCH_2Ph$, $NHC(O)$ -heterocycle, $-NHC(O)NHR$ or $-NHC(O)N(R)_2$;

- 20 3. A compound of claim 2, wherein

R is phenyl, mono or di-substituted phenyl, C_{3-6} cycloalkyl, C_{3-6} alkyl, C_{3-6} alkenyl or C_{3-6} cycloalkenyl;

- 25 R^2 is phenyl or substituted phenyl;

R^B is hydroxy, $-OC(O)R^x$, $-OC(O)OR^x$, $OP(O)(OH)_2$, $OCH_2OP(O)(OH)_2$, $-OCH_2OCH_2OP(=O)(OH)_2$, $OP(O)(OH)_2$ base, $OCH_2OP(O)(OH)_2$ base, $-OCH_2OCH_2OP(=O)(OH)_2$ base, $-(OCH_2)_mOC=OCH_2NHR^x$,
 30 $-(OCH_2)_mOC(=O)CH(R'')NR'_6R'_7$ where m is 0-3, $-OCOCH_2CH_2NH_3^+$, $HCOO^-$, $-OCOCH_2CH_2COOH$, $-OCO(CH_2)_3COOH$, $-OC(O)(CH_2)_nNR^FR^G$, where n is 0-3, $-OC(O)CH_2CH_2C(O)OCH_2CH_2OH$ or $-OC(O)-Z-C(O)-R'$;

- 35 R^{10} is hydrogen, hydroxy, $-OC(O)R^x$, $-OC(O)OR^x$, $-O-C_{1-6}$ alkyl or $-OCH_2OCH_3$;

4. A compound of claim 3, wherein

R^A is -NHC(O)O-(C₁₋₆)alkyl, -NHC(O)OCH₂Ph, -NHC(O)Ph or NHC(O)-2-furyl;

5 R^B is hydroxy;

R₄ is C₁₋₃ alkyl, -O-C₁₋₂ alkyl or cyclopropyl;

10 R is phenyl, 4-methylphenyl, 4-chlorophenyl, 4-bromophenyl, 4-fluorophenyl or 4-methoxyphenyl;

R⁶ and R^{6'} are independently hydrogen; and

15 R¹⁹ is methyl.

5. A compound of claim 4, wherein

R^A is -NHC(O)OtBu or -NHC(O)Ph;

20 R is phenyl; and

R² is phenyl.

25 6. A compound of claim 5, wherein

R⁴ is -CH₃; and

30 R^{9'} and R^{7'} taken together can form part of a ring joined by -CH₂S(O)_q in which the carbon is attached at R^{9'} and the sulfur at R^{7'} and where q is 0-2, R⁹ is -OH, and R⁷ is hydrogen.

7. A compound of claim 6, wherein

35 R^A is -NHC(O)Ph; and

R^{9'} and R^{7'} taken together can form part of a ring joined by -CH₂S(O)₂ in which the carbon is attached at R^{9'} and the sulfur at R^{7'} and where R⁹ is -OH, and R⁷ is hydrogen.

8. A compound of claim 6, wherein

R^A is -NHC(O)OtBu; and

5

R^{9'} and R^{7'} taken together can form part of a ring joined by -CH₂S(O)₂ in which the carbon is attached at R^{9'} and the sulfur at R^{7'} and where R⁹ is -OH, and R⁷ is hydrogen.

10 9. A compound of claim 4, wherein

R² is phenyl; and

R⁹ and R^{9'} taken together can form a ketone.

15

10. A compound of claim 9, wherein

R⁷ is mercapto, -S-R^W, -S(O)-R^W, -S(O)₂R^W, -S-CN, -SC(O)R^x, -SC(O)OR^x, -SC(S)R^x, -SC(S)SR^x, -SC(O)NHR^x, -SC(O)NR'₆R'₇, -SCH₂OR, -SC(R^x)₂OR, -SCHR^xOR, -SCH₂OCH₂OCH₃, -SCH₂SR, -SC(R^x)₂SR or -SCHR^xSR; and

20

R^{7'} is hydrogen.

11. A compound of claim 10, wherein

25

R⁴ is CH₃.

12. A compound of claim 11, wherein

30 R^A is -NHC(O)OtBu or -NHC(O)Ph; and

R is phenyl.

13. A compound of claim 12, wherein

35

R^A is -NHC(O)Ph; and

R⁷ is mercapto.

14. A compound of claim 12, wherein

R^A is $-\text{NHC}(\text{O})\text{Ph}$; and

R^7 is $-\text{SCH}_2\text{OCH}_3$.

15. A compound of claim 12, wherein

R^A is $-\text{NHC}(\text{O})\text{Ph}$; and


R^7 is $-\text{SCH}_2\text{SCH}_3$.

16. A compound of claim 12, wherein

R^A is $-\text{NHC}(\text{O})\text{Ph}$; and

R^7 is $-\text{SCH}_3$.

17. A baccatin intermediate compound of formula II



II

wherein R^2 , R^4 , R^6 , R^6' , R^7 , R^7' , R^{19} , R^9 , R^9' , and R^{10} are as previously defined in claim 1.

18. A pharmaceutical formulation which comprises an antitumor effective amount of a compound of formula I as claimed in any one of claims 1-16.

19. A method for inhibiting tumor growth in a mammalian host which comprises administering to said mammal a tumor-growth inhibiting amount of a compound of formula I as claimed in any one of claims 1-16.

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US98/08082

A. CLASSIFICATION OF SUBJECT MATTER

IPC(6) : A01N 37/00

US CL : 514/511, 529

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 514/511, 529

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched
NONEElectronic data base consulted during the international search (name of data base and, where practicable, search terms used)
CA, REGISTRY, CAPLUS: structure search performed.

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	Database CA on STN, THE UPJOHN CO. USA. No. 121:280920, Hester et al., "Preparation of 7-halo- and 7.beta., 8.beta.-methanotaxols, their antineoplastic use and pharmaceutical compositions containing them", abstract to WO 94/13655 A1, 23 June 1994.	1-19

☐ Further documents are listed in the continuation of Box C. ☐ See patent family annex.

* Special categories of cited documents:	*T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
A document defining the general state of the art which is not considered to be of particular relevance	*X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
B earlier document published on or after the international filing date	*Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
L document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	*A* document member of the same patent family
O document referring to an oral disclosure, use, exhibition or other means	
P document published prior to the international filing date but later than the priority date claimed	

Date of the actual completion of the international search

22 JULY 1998

Date of mailing of the international search report

03 SEP 1998

Name and mailing address of the ISA/US
Commissioner of Patents and Trademarks
Box PCT
Washington, D.C. 20231

Facsimile No. (703) 305-3230

Authorized officer

DWAYNE C. JONES

Telephone No. (703) 305-3741